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 INTRODUCTION  
 
 Jean Athanase Sicard and Fernand Cathelin independently introduced cocaine 
through sacral hiatus in 1901, thereby becoming the first practitioners of caudal 
(epidural) anesthesia.  
 
Twenty years later, Fidel Pages described the interspinous approach to the 
epidural space and reported satisfactory anesthesia for intra-abdominal 
procedures. In 1945, Tuohy introduced the epidural needle but it was Eugene 
Aburel who introduced a silk ureteral catheter in the epidural space and used it 
to block the pain of labor in women. By 1962, the first polyvinyl catheter with a 
closed tip was introduced, making the continuous epidural block much easier to 
perform in an efficient way. 
 
Epidural blockade
2 
has a unique special feature of segmental blockade where by 
only the desired segments required for surgical plane are blocked, unlike the 
uncontrolled level of blockade as occurs in spinal anesthesia. The period of 
analgesia can be extended to the post-operative period through the continuous 
catheters. 
 
Ever since the administration of local anesthetics in epidural route, there has 
been many adjuvants (adrenaline, opioids, alpha-2 agonists, ketamine,  
 
 neostigmine) that are added to shorten the onset of action, improve the quality 
of analgesia and prolong the duration of analgesia in the post-operative period. 
 
Magnesium sulphate has been added as an adjuvant in neuraxial blockade. It  
has been known to possess anti-nociceptic property in intravenous route in the 
perioperative and the postoperative period. The site of action of magnesium has 
been explained by the property of NMDA receptor antagonism which has 
prevented central sensitisation to peripheral nociceptive stimulation. There are 
many studies to prove its potency as an analgesic. Its clinical efficacy and safety 
has been proved in humans in experimental studies.  
 
In this Prospective Randomised Double blind controlled study we evaluated the 
onset of action of magnesium sulphate in epidural anesthesia in patients coming 
for lower abdominal surgeries. 
 
 
 
 
 
 
 
 
 
 EPIDURAL NEURAL BLOCKADE 
 
Epidural neural blockade
1, 2
 is a type of neuraxial blockade where the 
improvement in drugs, equipment and technique has made it a popular and 
versatile technique with its wide applications in surgery, obstetrics and pain 
medicine. Both single injection and continuous injections with catheters are 
used.  
 
It is unique in that it can be placed virtually at any level of the spine, allowing 
more flexibility in its application to clinical practice. It is more versatile than 
spinal anesthesia, giving the clinician the opportunity to provide anesthesia and 
analgesia, as well as enabling diagnosis and treatment of chronic disease 
syndromes.  
 
It can be used to supplement general anesthesia, decreasing the need for deep 
levels of general anesthesia, therefore providing a more hemodynamically stable 
operative course and faster emergence from general anesthesia. It provides 
better postoperative pain control and more rapid recovery from surgery.   
 
 
 
  
 
 ANATOMY 
3, 5
  
The vertebral column consists of 7 cervical, 12 thoracic, and 5 lumbar 
vertebrae. At the caudal end, the 5 sacral vertebrae are fused to form the sacrum, 
and the 4 coccygeal vertebrae are fused to form the coccyx . The primary 
functions of the vertebral column are to maintain erect posture, to encase and 
protect the spinal cord, and to provide attachment sites for the muscles 
responsible for movements of the head and trunk. The normal spinal column is 
straight when viewed dorsally or ventrally. When viewed from the side, there 
are two ventrally convex curvatures in the cervical and lumbar regions, giving 
the spinal column the appearance of a double "C". 
 
The shape and size of the vertebrae differ from the cervical to the lumbar region 
secondary to function. The vertebral bodies are smaller in the cervical region an 
become progressively larger in the lumbar area where they support the greatest 
amount of weight.  
 
The spinal canal is formed by adjacent vertebral foramina. The canal provides 
support and protection to the spinal cord and its nerve roots. The spinal cord 
extends from the foramen magnum to the L1-2 vertebral level in adults, and L3 
vertebral level in children before becoming the conus medullaris. 
 
From the spinal cord extends a series of dorsal and ventral roots that converge 
to form mixed spinal nerves. The mixed nerves contain motor, sensory, and in  
 many cases, autonomic fibers. There are eight cervical, 12 thoracic, 5 lumbar, 5 
sacral, and 1 coccygeal pairs of spinal nerves. 
When performing an epidural, the needle passes through the following: 
 Skin                                                    
 subcutaneous fat                      
 supraspinous ligament 
 interspinous ligament 
 ligamentum flavum                          
 
Surrounding the spinal cord and its roots are three layers of membranes. The 
innermost layer is called the pia mater, which attaches intimately to the surface 
of the spinal cord and roots of the spinal nerves. As the roots of the spinal 
nerves extend distally, the pia mater transforms into the second layer called the 
arachnoid. The arachnoid detaches from the roots and reflects back across the 
pia, enclosing the spinal cord within a cavity called the subarachnoid space. The 
space is filled with cerebrospinal fluid and transmits blood vessels to and from 
the spinal cord. Superficial to the arachnoid is the thick dura mater. The space 
between the arachnoid and dura is called the subdural space.  
 
 
 
 
 ANATOMY OF EPIDURAL SPACE: 
 
The epidural space is smaller than the subarachnoid space, extends from the 
base of the skull to the sacral hiatus, and surrounds the dura mater anteriorly, 
laterally, and posteriorly. The epidural space is bound posteriorly by the 
ligamentum flavum and laterally by the pedicles and the intervertebral 
foramina. It is filled with the fat, areolar tissue, lymphatics, veins, and nerve 
roots that traverse it, but there is no free fluid. 
The epidural space is rich in blood vessels, including Batson's venous plexus. 
Batson's plexus is continuous with the iliac vessels in the pelvis and the azygos 
system in the abdominal and thoracic body walls. Because this plexus has no 
valves, blood from any of the connected systems can flow into the epidural  
 vessels. This is especially important in obstetrics when compressed caval 
vessels can lead to engorgement of the epidural veins, increasing the risk of 
catheter entry into a vein. The engorgement is even greater at the intervertebral 
foramina where the vessels may bulge from the vertebral canal. Therefore, the 
incidence of penetrating a blood vessel with an "off-midline" needle insertion 
may be more likely. 
The distance from the skin to epidural space is 4 to 5 cm in 80% of the 
population. It is shorter in lean individuals and deeper in obese individuals. 
Characteristics of the Ligamentum Flavum at Different Vertebral 
Levels
1
 
Site 
Distance from Skin to 
Ligament (cm) 
Thickness of 
Ligament (mm) 
Cervical — 1.5-3.0 
Thoracic — 3.0-5.0 
Lumbar 3.0-8.0 5.0-6.0 
Caudal Variable 2.0-6.0 
 
PHYSIOLOGICAL EFFECTS OF EPIDURAL BLOCKADE:  
The primary site of action of local anesthetic solutions injected into the epidural 
space is the spinal nerve roots. The segmental nerve roots in the thoracic and 
lumbar regions are mixed nerves, containing somatic sensory, motor, and  
 autonomic nerve fibers. Sensory blockade interrupts the transmission of both 
somatic and visceral painful stimuli, whereas motor blockade provides muscle 
relaxation with a varying degree of sympathetic blockade. 
 
 CARDIOVASCULAR - The effect of epidural anesthesia on the 
cardiovascular system depends on the level and the degree of sympathetic 
blockade. Vasomotor tone is maintained by sympathetic fibers from T5 to 
L1 that innervate vascular smooth muscle. Blockade of these fibers cause 
venodilation with venous pooling as well as arterial vasodilation with 
decreased systemic vascular resistance. 
 
 RESPIRATORY - Epidural blockade to midthoracic levels have 
minimal effect on patients with adequate lung function. Lung volumes 
(tidal volume, vital capacity), resting minute ventilation, and dead space 
are basically unchanged even with a high thoracic epidural anesthesia. 
Even with abdominal or intercostal muscle paralysis by a high thoracic 
block, major alteration in pulmonary function is not seen. 
 GASTROINTESTINAL - The gastrointestinal effects of epidural 
anesthesia are largely the result of blockage of the sympathetic splanchnic 
fibers from the T5 through L1 level. Unopposed vagal dominance leads to 
an increase in secretions; peristalsis; and a smaller, contracted gut. 
 
 
 
  RENAL - Since renal blood flow is maintained through autoregulation, 
epidural anesthesia has very little effect on renal function. Urinary 
retention occurs until the regression of blockade. 
 
 NEUROENDOCRINE – The stress hormones epinephrine, 
norepinephrine , vasopressin etc., released during surgical stimulus are 
reduced. 
 
PHARMACOLOGY OF THE LOCAL ANESTHETIC ACTION: 
Local anesthetic binds to sodium channels, primarily in the inactivated state, 
preventing further channel activation. Sodium ion movement into the cell is 
prevented, effectively blocking the development of the action potential. The 
resulting resting membrane potential is unaffected by further nerve stimulation, 
referred to as membrane stabilization of local anesthetics. 
 
Within the dorsal horn, local anesthetics can block both sodium and potassium 
ion channels in the dorsal horn neurons, inhibiting the generation and 
propagation of pain signals (nociceptive electrical activity). Motor blockade 
occurs from a similar action on the ventral horn neurons. Blockade of calcium 
ion channels in the spinal cord leads to resistance of electrical stimulation from 
nociceptive afferent nerves, creating an intense analgesic action seen in 
centrally administered  local anesthetics. 
 
 A variety of other classes of drugs have been studied more recently to try to 
improve the quality of neuraxial blockade, in the epidural space. In addition to a 
variety of opioids (eg, fentanyl,sufentanil), alpha-adrenergic agonists, 
cholinesterase inhibitors, semisynthetic opioid agonist–antagonists, ketamine, 
and midazolam have been studied with varied results. 
 
Volume is the key factor in determining the height of block.. A larger volume 
will block a greater number of segments. A generally accepted guideline for 
dosing an epidural  blockade  in adults is 1–2 mL per segment to be blocked. 
This guideline should be adjusted for both short and tall patients. 
 
Time to repeat a dose of local anesthetics depends on the duration of action of 
the drug. Doses should be administered before the block regresses to the point 
where the patient experiences pain, commonly referred
2
 to as "time to two-
segment regression." This is defined as the time it takes for the sensory block 
to regress by two dermatome levels. When two-segment regression has 
occurred, one-third to one-half of the initial loading dose can safely be 
administered to maintain the block. 
TECHNIQUE:  
Equipments required: 18 G or 16G , 9 cm Tuohy needle ,with a 15-20 degrees 
angulation at the tip (Hueber’ s tip), 18 G epidural catheter, 5 ml syringe (for 
LOR ), 2 ml syringe, local anesthetic preparation of 1.5 % lignocaine, filter. 
 
 Position: sitting / lateral decubitus position. 
Approach: Midline, Paramedian. 
                                          
Procedure: 1. Confirm the regions of desired blockade. 2. Local anesthetic 
infiltration of the skin should be administered judiciously. 3. The epidural 
needle is inserted into the interspinous space. 4. Epidural space is located using 
the Loss of resistance technique or the Hanging drop sign. 5. The catheter is 
then threaded and placed 4 to 5 cm in the epidural space. 6. 3 ml of 1.5 % 
lignocaine with 1 in 2,00,000 adrenaline is given through the catheter and  
 misplacement into the subarachnoid, intravascular and subdural space  ruled 
out. 7. The catheter is then secured.  
FACTORS AFFECTING THE LOCAL ANESTHETIC ACTION: 
1. Site of injection – after lumbar injection there is more cranial spread of 
the local anesthetic. In thoracic blockade there is equal spread.  
2. Volume – lumbar segments require 1.5 to 2 ml per segment .Thoracic 
segments require 1 to 1.5 ml per segment. 
3. Age – in old age there is narrowing of the interspinous process, due to 
calcification of the ligaments. 
4. Height – shorter individuals require less volume of anesthetic. 
5. Weight – obese individual require less volume due to narrowing of the 
interspinous spaces and engorgement of the epidural venous plexus. 
6. Posture – In epidural anesthesia posture has no significant change. 
7. Alkalinisation of local anesthetics – increasing the pH of the local 
anesthetic potentiates the onset of action. 
8. Adjuvants – Addition of other adjuvants like epinephrine , opioids etc., 
potentiates the action and improves the quality of blockade. 
 
 
 
 
 
  INDICATIONS: 
Epidural anesthesia/analgesia is administered in the following  
1. Abdominal surgeries. 
2. Lower limb surgeries 
3. Obstetric & Gynaecological surgeries. 
4. Urological surgeries 
5. Orthopaedic surgeries 
6. Vascular surgeries 
7. Thoracic surgeries 
8. Along with general anesthesia for post-op analgesia 
9. Labor analgesia 
10. Management of chronic pain 
 
CONTRAINDICATIONS: 
The following are the contraindications for epidural blockade 
Absolute Relative 
Patient refusal Coagulopathy 
Increased ICP Spine deformity 
Localised infection Un co-operative patient 
Hypovolemia Neurological disorders 
 
 
 SIDE EFFECTS: 
Following are the side effects of epidural blockade 
1. Hypotension 
2. Inadvertent high blockade 
3. Post dural puncture headache 
4. Local anesthetic toxicity 
5. Inadvertent high spinal 
6. Hematoma 
7. Infection- Epidural abscess, Meningitis 
8. Allergy to local anesthetics 
9. Anterior spinal artery syndrome 
10. Arachnoiditis and Transverse myelitis. 
 
 
 
FAILURE OF EPIDURAL ANESTHESIA : 
 
Entry into the epidural space is purely tactile, and the end point of entry is  
subject to  misinterpretation. There are false losses of resistance, and quite often  
the only  proof that the needle was correctly positioned is that the resulting  
block is effective.  
 
The introduction of a catheter into the epidural space introduces an additional 
number of reasons for the failure of epidural anesthesia. The inability to pass a  
 catheter into the epidural space frequently indicates that the needle is not in the  
epidural space. Catheters may become occluded with blood, or the catheter may  
kink, take a unilateral course, break, or become knotted, all of which can  
contribute  to the  failure of epidural anesthesia. 
 
An important distinction that should be made during epidural catheter threading 
is that of complete failure versus a partial blockade/failure. Epidural local  
anesthetic dosing for anesthesia may approach the maximum safe limit,  
preventing significant further administration of local anesthetic. Thus, a failed  
epidural may prompt the clinician to pursue an alternative course of anesthesia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGY OF BUPIVACAINE
  
 
 
 
Bupivacaine
6
 is an amide group of pipecoloxylidide local anesthetic. 
Bupivacaine is formed by addition of a butyl group to the piperidine nitrogen of 
Mepivacaine making it 35 times more potent. Local anesthetics prevent 
transmission of nerve impulses (conduction blockade) by inhibiting the passage 
of sodium ions through selective sodium channels in nerve membranes. 
However, they do not alter the resting membrane potential or threshold 
potential. 
Bupivacaine binds to alpha subunit of the sodium channel 
 
Na
+
 channels exist in activated-open, inactivated-closed and resting-closed 
states 
 
Bupivacaine selectively binds to sodium channels in inactivated-closed state 
                
               Prevent their change to rested- closed, activated-open states. 
 
Sodium channels are not permeable in inactivated-closed state 
 
NO conduction of impulses and NO action potential occurs 
 
Frequency dependent blockade:   Sodium ion channels tend to recover from 
local anesthetics induced conduction blockade between action potentials and to 
develop additional conductional blockade. Local anesthetics gain access to 
receptors only when sodium channels are in activated-open states. So, a resting 
nerve is less sensitive to conduction blockade than a repetitively stimulated 
nerve. 
 
Other site of Action Targets: In addition to sodium channels bupivacaine blocks 
voltage dependent potassium ion channels. This explains the reason for 
broadening of action potential. Bupivacaine also blocks the calcium ion 
channels (L-type). 
 
Bupivacaine blocks both types of pain fibres, myelinated A-delta and 
unmyelinated C-fibres. Preganglionic-B fibres are readily blocked by local 
anesthetics than the other two nerve fibres. 
 
PHARMACOKINETICS: 
 
Bupivacaine is a weak base that has a pKa value above the physiological pH. 
Hence only less amount of the drug is in non-ionised form. Acidosis increases  
 
 the pH of the medium causing more ionised fraction of drug resulting in poor 
quality of anesthesia. 
 
Absorption of the drug depends on site of injection, its dosage, adjuvants such 
as epinephrine,opioids ,and the pharmacological characteristics of the drug. The 
plasma concentration is determined by the rate of tissue distribution and rate of 
clearance. 
 
The lungs are capable of extraction of bupivacaine from the systemic circulation 
and its first pass pulmonary extraction is dose dependent. 
 
Bupivacaine binds to the plasma protein alpha-1 acid glycoprotein. It undergoes 
aromatic hydroxylation, N-dealkylation, amide hydrolysis and conjugation. 
 
 
 USES: 
Regional Anesthesia – (i) local infiltration (ii) peripheral nerve block (iii) 
Epidural anesthesia (iv) Spinal anesthesia (v) Topical anesthesia  
 
SIDE EFFECTS: 
1. Allergic reactions 
2. Neurotoxicity – tinnitus, vertigo , muscle twitches , slurred speech and 
seizures. 
3. Cardiotoxicity – precipitous hypotension, cardiac dysrhythmias and 
atrioventricular blocks. 
4. Hepatotoxicity 
 
 
 
Onset Slow 
Duration of action 240-480 mins 
pKa 8.1 
Protein binding >97% 
Potency 4 
Toxic plasma concentration >3µg/ml 
Lipid solubility 28 
Volume of distribution 73 litres 
Clearance 0.47 litres/min 
Elimination half time 210 mins 
  PHARMACOLOGY OF MAGNESIUM SULPHATE 
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Magnesium is the fourth most common cation in the body and the second most 
common intracellular cation after potassium. Magnesium plays a fundamental 
role as a cofactor in many enzymatic reactions involving energy metabolism 
and nucleic acid synthesis. it is also involved in several processes including: 
hormone receptor binding ;gating of calcium channels; transmembrane ion flux; 
muscle contraction; neuronal activity; control of vasomotor tone; cardiac 
excitability and neurotransmitter release.  
 
Magnesium is distributed principally in bone (53%), intracellular compartments 
of muscle (27%) and soft tissues (19%). Serum magnesium comprises only 
0.3% of total body magnesium stores. It is present in 3 forms  
1. Ionised (62%) 
2. Protein bound(33%),mainly albumin 
3. Bound to citrate and phosphate (5%) 
Magnesium is absorbed in the ileum and colon. Its absorption is inversely 
proportional to intake. Excretion occurs via the kidney .along with the other  
 cations magnesium is filtered at the glomerulus, but reabsorption occurs in the 
ascending loop of henle and not proximal convoluted tubule. 
 
Magnesium in its many of its properties mimics a physiological calcium 
antagonist.  A common pathway for the release of hormones, growth factors, 
and neurotransmitters is phospholipase C activation and hydrolysis to inositol 4, 
5 triphosphate (IP3). This (IP3) binds to the calcium channels and releases 
calcium. Magnesium is a non-competitive inhibitor of the (IP3) gated calcium 
channel. It may also inhibit the ryanodine receptors to release calcium ions in 
the sarcoplasmic reticulum. 
 
Only 0.3% of the total body magnesium is available in serum for estimation. 
Henceforth estimation of serum levels does not reflect the total body 
magnesium stores. Normal serum magnesium levels are 1.5 – 2.5 mEq/L. When 
the levels are below 1.5mEq/L it is called as HYPOMAGNESEMIA. When 
the levels are greater than 2.5mEq/L it is termed as HYPERMAGNESEMIA. 
Another parameter for estimation is 24hr urinary magnesium concentration 
which is 5-15 mEq/24hr. 
 
MAGNESIUM DEFICIENCY: 
Magnesium deficiency is often multifactorial and is usually found to coexist 
along with other electrolyte abnormalities, particularly hypokalemia or 
hypophoshatemia. Following are the causes for magnesium deficiency (i) 
reduced intake (ii) poor G.I. absorption (iii) increased losses through diarrhoea,  
 vomiting (iv) increased renal losses (v) diabetes mellitus (vi) alcoholism (vii) 
drug induced – diuretics, aminoglycosides etc, 
 
Clinical features: (i) usually assosciated with hypocalcemia and hypokalemia 
(ii) arrhythmia- Torsades de pointes, a polymorphic ventricular tachycardia (iii) 
neurologic manifestations include altered mentation, seizures, tremors and 
hyperreflexia. 
 
A serum concentration of less than 1 mEq/L is treated with 6 g magnesium 
sulphate in 250 ml isotonic saline and infused over 3 hours followed by 5 g 
magnesium sulphate over next hours. Continue with 5 g magnesium sulphate 
every 12 hours for next 5 days. 
 
MAGNESIUM TOXICITY: 
Serum magnesium levels more than 2.5 mEq/L is termed as hypermagnesemia. 
Following are the causes: (i) hemolysis from haemolytic anemia or trauma (ii) 
renal insufficiency (iii) diabetic ketoacidosis (iv) adrenal insufficiency (v) 
hyperparathyroidism (vi) lithium intoxication. 
 
 
 
 
 
 
Following are the clinical features. 
Manifestation Serum magnesium (mEq/L) 
Hyporeflexia >4 
1 st degree AV block >5 
Complete heart block >10 
Cardiac arrest >13 
  
Management is by (i) hemodialysis is the treatment of choice for severe 
hypermagnesemia (ii) intravenous calcium gluconate 1 g over 2-3 mins is used 
to antagonise the cardiovascular effects (iii) aggressive volume infusion with 
furosemide. 
 
 
MAGNESIUM SULPHATE IN OBSTETRICS: 
Magnesium sulphate remains the drug of choice in the treatment eclampsia. 4 to 
6 gm i.v. magnesium sulphate is diluted in 100 ml of normal saline given over 
15 mins. This is followed by infusion of 2 gm/hr i.v. in 100 ml normal saline. 
Target serum magnesium levels are 4 to 7 mEq/L. 
 
Another alternative regimen is Pritchard’s regimen: 4gm magnesium sulphate 
given slow i.v. followed by 10 gm, of which 5 g is given in each buttocks as 
deep i.m.injection. Use of magnesium sulphate in cases of pre-eclampsia is yet 
to be proven. 
 
Magnesium sulphate is known to have tocolytic effect. An i.v.bolus of 2-4 g 
over 24 hrs followed by 1-2 g/hr i.v.infusion and is regulated based on uterine 
responses. Tocolysis is known to be effective with a target serum level of 8 
mEq/L. 
Obervational studies have proven the decrease in incidence of cerebral palsy in 
low birth infants in mothers treated with magnesium sulphate. 
 
 
MAGNESIUM SULPHATE IN CARDIOLOGY: 
It acts on calcium channels in the myocardial muscle and also acts indirectly on 
the cardiac muscle by inhibiting the calcium uptake on the Troponin C of the 
myocytes and thereby influencing myocardial contractility. Its vasodilatory 
action is due to its activation of cyclic AMP. This causes reduction in systolic 
blood pressure. Pulmonary vascular resistance is unaltered. Coronary vascular 
resistance is reduced and causes vasodilation. 
 
Uses:  
1.  In acute Myocardial infarction – 2 gm Magnesium sulphate 
intravenously over 5 to 15 mins followed by 18 gm over 24 hours. 
2. In the treatment of arrhythmias-(i) Torsades de pointes intravenously 25 
to 50 mg/kg, can be given upto 2 gm.(ii) in atrial or ventricular 
arrhythmias along with hypokalemia. 
3. Hypomagnesemia is common after CABG, henceforth its use in 
postoperative period prevents arrhythmias. 
 
 MAGNESIUM IN NEUROMUSCULAR BLOCK: 
Magnesium ions have an inhibitory effect on postjunctional potentials and 
decrease in muscle fibre membrane excitability. It also has a preponderant 
action on presynaptic potentials by competitively blocking the entry of calcium  
 
ions. Presynaptic inhibition in release of acetylcholine decreases the effect on 
postsynaptic receptors which in turn increases the threshold of axonal 
excitation, thereby potentiating the neuromuscular blockade action.  
 
MAGNESIUM IN CENTRAL NERVOUS SYSTEM: 
Magnesium sulphate has been found to possess NMDA receptor antagonistic 
property thereby inhibits induction and central sensitisation after nociceptive 
stimuli. 
 
In many studies magnesium is found to possess the analgesic property when 
administered by intravenous, intrathecal and epidural routes. Magnesium when 
administered intravenously dosage varies from 30mg to 50 mg per kg body 
weight. In the neuraxial blockade a dosage of 50 mg has been found to have 
desired analgesia. Therefore this explains its use in intraoperative and 
postoperative analgesia. 
 
Nephritic Seizures: In children with nephritic seizures, the 50% concentration 
should be diluted to a 20% solution for i.m. injection. The dose for children is 
20 to 40 mg (0.1 to 0.2 mL of a 20% solution)/kg of body weight, administered 
i.m. as needed, to control seizures. 
 
Magnesium as already explained possesses anti-epileptic property in Eclampsia, 
although its effect on other types of seizures is yet to be proved. 
 
 
MAGNESIUM IN RESPIRATORY SYSTEM: 
It has bronchodilatory action due to the inhibition of smooth muscle 
contraction, histamine release from the mast cells and acetylcholine release 
from the cholinergic nerve endings. This explains its use in bronchial asthma. 
 
MAGNESIUM DECREASES CATECHOLAMINE RELEASE: 
Magnesium is known to have marked anti adrenergic effect, which is mediated 
by calcium antagonism. This anti-adrenergic property along with vasodilatory 
and anti-arrhythmic effect makes its use beneficiary in Pheochromocytoma. 
 
This property facilitates its use for nullifying the stress response for tracheal 
intubation. To reduce the stress response during intubation, magnesium sulphate 
is used in the dosage of 30-50mg/kg intravenously. 
 
PREPARATIONS AVAILABLE: 
 Magnesium sulphate- 10%, 12.5%, 50%, 4%, 8%. 
When administered intravenously the onset of action is immediate and 
duration of action is 30 min. On administration by intramuscular route the 
onset of action takes 1hr and duration of action is 3-4 hrs. For IV use 
concentration of 20% or less should be used. Rate of injection should be 
1.5ml/hr 
Storage: 15-30degree centigrade 
. 
 
 
DRUG INTERACTIONS: 
 Central nervous system depressants: When barbiturates, opiates, general 
anaesthetics, or other CNS depressants are administered concomitantly 
with magnesium sulphate, dosage of these agents must be carefully 
adjusted because of the additive central depressant effects. 
 
 Neuromuscular blocking agents: Excessive neuromuscular blockade has 
occurred in patients receiving parenteral magnesium sulphate and a 
neuromuscular blocking agent; these drugs should be administered 
concomitantly only with caution. 
 
 Cardiac glycosides: Magnesium salts should be administered with 
extreme caution in digitalized patients, because serious changes in cardiac 
conduction, which can result in heart block may occur if administration of 
calcium is required to treat magnesium toxicity. 
 
 
 
ADVERSE REACTIONS: 
The adverse effects of parenterally administered magnesium usually 
are the result of magnesium intoxication. These include flushing, sweating, 
hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory 
collapse, cardiac and CNS depression proceeding to respiratory paralysis. 
 
Hypocalcemia with signs of tetany secondary to magnesium sulphate 
therapy for eclampsia, has been reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
1)Tanmoy et al
8
, had done a study on evaluation of the effect of adding 
magnesium sulphate or clondine in the epidural route along with bupivacaine in 
patients coming for lower abdominal and lower limb surgeries. Study groups 
were divided into Group B which received 1 ml magnesium sulphate (50 mg) + 
19 ml 0.5% bupivacaine, Group C which received 1 ml clonidine (150 mcg) 
+19 ml 0.5%bupivacaine  and control Group A which received same volume of 
normal saline along with 19 ml 0.5% bupivacaine.  
The time taken for onset of sensory blockade at T6 level was least in Group B   
(11.80 ± 3.21 minutes) highest in control Group A (18.73 ± 2.79 minutes) and 
in Group C was 16.93 ± 3.43 minutes. The difference was statistically 
significant (p<0.05). The early onset of action in the magnesium group was 
explained by the property of NMDA receptor antagonism which has prevented 
central sensitisation to peripheral nociceptive stimulation. 
 The time for first epidural top up in Group B was 161.67 ± 30.10 minutes, 
Group C 180.33 ± 29.97 minutes and in Group A 150.67 ± 35.80 minutes. The 
time for two segment regression in Group B 130.33 ± 39.34 minutes ,Group C 
145.33 ± 27.74 minutes and in control Group A 123.0 ± 28.08 minutes. The 
duration of action was longer in the Clonidine group.  
The incidence of shivering was 13.3% in control group, 33.3% in clonidine 
group and no cases reported in magnesium group. 
 
 
They study concluded that co-administration of epidural magnesium sulphate 
with bupivacaine produces predictable rapid onset of surgical anesthesia 
without any side effects and addition of clonidine to epidural bupivacaine 
produces prolonged analgesia with sedation.  
 
2) A.Bilir 
9
 et al , had conducted a study on the effect of adding epidural 
magnesium sulphate for post-operative analgesia in patients undergoing hip 
surgery. After the surgery patients were made to receive patient controlled 
epidural analgesia (PCEA). Patients received 25 mcg fentanyl with a lock out 
interval of 20 min and 4 hr limit of 150 mcg fentanyl. Patients were ascertained 
into two groups, Group FM received 50 mg magnesium sulphate bolus followed 
by continuous infusion of 100 mg magnesium sulphate for 24 hr period and the 
other Group F received similar volume of normal saline.  
The cumulative fentanyl consumption in 24 hr period was 437 mcg in Group F, 
while in Group FM it was 328 mcg which was statistically significant (p< 0.05). 
There was no significant side effect in both groups.  The study concluded that 
coadministration of magnesium for post-operative epidural analgesia reduces 
fentanyl consumption with no side effects. 
 
3) S.Farouk 
10
, had conducted a study to evaluate preventive and preemptive 
analgesic efficacy of adding magnesium sulphate to a multimodal regimen of 
patient controlled analgesia (PCEA) in patients undergoing abdominal 
hysterectomy.  
 
Three groups were randomly categorised. In the pre-magnesium group 50 mg 
magnesium sulphate was given before induction followed by 10 mg/hr until the 
end of surgery. In the post magnesium group 50 mg magnesium sulphate was 
given after the surgery with no infusions and the control group received equal 
volume of saline throughout the course. Surgery was proceeded under general 
anesthesia. Patients in the magnesium groups received PCEA with fentanyl 1 
µg/ ml, bupivacaine 0.08%, and magnesium 1 µg/ml after operation. Patients in 
the control group received PCEA with fentanyl 1 µg/ml and bupivacaine 0.08%. 
There was significant lower pain scores in the pre-magnesium group (p <0.05) 
and the opioid dose consumed in the post-magnesium group was less than in the 
control group (p< 0.05). There were no significant side effects in all the groups.  
The study was concluded that continuous epidural magnesium started before 
anesthesia provided preventive, preemptive analgesia and an analgesic sparing 
effect that improved the postoperative analgesia without any side effects. 
 
4) Yousef
11
 et al, had conducted a study to evaluate the effect of adding 
magnesium sulphate to epidural bupivacaine and fentanyl in elective caesarean 
section using combined epidural and spinal anesthesia. 
All patients received 2 mL intrathecal 0.5% hyperbaric bupivacaine, 10 mL 
epidural 0.25% plain bupivacaine with fentanyl 100 μg, and were randomly 
allocated in to two groups to receive either 10 mL of epidural 0.9% sodium 
chloride or 10 mL epidural 5% magnesium sulphate.  
 
 It was found that women who received epidural magnesium had a greater 
muscle relaxation (p<0.05). APGAR scores were > 7. Women who received 
magnesium showed less shivering and later onset of post operative pain 
(P<0.05). 
The addition of magnesium to epidural bupivacaine and fentanyl in women 
undergoing elective caesarean section with combined spinal-epidural 
anaesthesia improved intraoperative conditions and the quality of postoperative 
analgesia. 
 
5) Aricioni
17
 et al, had conducted a, double-blind, placebo-controlled trial, with 
120 consecutive patients undergoing orthopedic surgery during spinal 
anesthesia (levobupivacaine and sufentanil). Patients were randomly assigned to 
receive intrathecal MgSO4 (94.5 mg, 6.3%), epidural MgSO4 (2%, 100 mg/h), 
intrathecal and epidural MgSO4 combined or spinal anesthesia alone (controls). 
Post-operative morphine consumption was assessed in all groups by patient-
controlled analgesia (PCA) 
Morphine consumption at 36 h after surgery was 38% lower in patients 
receiving spinal anesthesia plus epidural MgSO4. 49% lower in those receiving 
spinal anesthesia plus intrathecal MgSO4 and 69% lower in the intrathecal-
epidural combined group relative to control patients receiving spinal anesthesia 
alone. 
 
 
 6) H.Birbicer
13
 et al, had conducted a study of adding magnesium sulphate in 
caudal epidural in children coming for penoscrotal and lower abdominal 
surgeries. Two groups were randomly ascertained. The study group received 
magnesium sulphate 50 mg while the control group received equal volume 
saline,along with 0.25 % ropivacaine after the induction of general anesthesia. 
The postoperative analgesic consumption did not show statistical significance 
(p>0.05) and the analgesic requirements were equal in both the groups. 
 
7) Jong Wha Lee
15
 et al , conducted a study to evaluate the analgesic effect of 
magnesium sulphate administered intrathecally. Two groups were made in 
random. The study group received 50 mg magnesium sulphate with 10 mg 
tetracaine while the control group received equal volume saline along with 10 
mg tetracaine. Postoperative rescue analgesic contained 0.2% ropivacaine in the 
Magnesium group and 0.2% ropivacaine  plus morphine in the control group via 
epidural catheter. 
 The VRS score at 120 minutes after the IT injection were lower in group M 
than in group C (p ＜ 0.05). There were no differences in the VRS scores and 
the use of supplemental analgesics at the postoperative period. The incidence of 
PONV, pruritus and urinary retention was significantly lower in group M than 
in group C at 12 and 36 hours after surgery. 
 
8)M.Ozalevli 
12 
et al, had conducted a study on the effect of adding magnesium 
sulphate to bupivacaine-fentanyl spinal anesthesia. The study group received 50  
 mg magnesium sulphate along with fentanyl while the control group received 
bupivacaine with fentanyl and same volume of 0.9 % preservative free normal 
saline.  
The mean duration of analgesia was longer in the magnesium group (p <0.001). 
The study concluded that addition of magnesium sulphate prolongs spinal 
opioid analgesia. 
 
9) Asokkumar Buvenendran
14
 et al, had conducted a study on adding 
magnesium sulphate along with fentanyl in combined spinal – epidural labor 
analgesia. The study group received 25 mcg fentanyl and 50 mg magnesium 
sulphate while the control group received fentanyl 25 mcg and normal saline.  
The median duration of analgesia in the magnesium group was 75 minutes 
while in the saline group it was 60 mins. In conclusion it was demonstrated that 
addition of magnesium sulphate prolongs the opioid analgesia.    
 
10)Khalili 
37
 et al , had conducted a study on the effect of adding magnesium 
sulphate as an adjunct to bupivacaine for spinal anesthesia in patients 
undergoing lower extremity surgeries. Two groups were randomnly 
selected,one group received 100 mg magnesium sulphate with 15 mg 
bupivacaine and the other group received 15 mg bupivacaine with normal saline 
(0.2 ml). The onset of sensory blockade was slower with magnesium p=0.04, 
but the duration of sensory blockade was longer p=0.001. In conclusion addition  
 
 of magnesium sulphate to spinal anesthesia prolonged the duration of sensory 
block and decreased postoperative analgesic requirement. 
 
11) Martin R.Tramer 
33
 et al, had conducted a study on effect of administering  
magnesium sulphate intravenously in the perioperative period. The study group 
received 20%magnesium sulphate 15 ml intravenously before the surgery and 
2.5ml/hr for the next 20 hours. The control group received similar volume of 
saline. Post operative morphine consumption using patient controlled analgesia 
was assessed for 48 hours.  
During the first 48 hours morphine consumption was reduced in the magnesium 
group with a significant p<0.03, which was more pronounced at the 6 th hour 
(p<0.004).  In the second and the third postoperative days there was less 
discomfort (p<0.05). The study concluded that perioperative administration of 
magnesium sulphate reduces postoperative analgesia requirement with no 
adverse effects. 
 
12)Michael.F.James 
18
 et al, had conducted a study on the effect of 60 mg/kg 
intravenous magnesium sulphate pretreatment on cardiovascular responses and 
catecholamine release associated with tracheal intubation. The effects were 
measured in 15 study group patients and in 15 saline solution pre-treated 
controls. After intubation, heart rate was unchanged in the magnesium group at 
107.3 ± 3.6 beats/minute but increased in the control group to 120.9 ± 4.6 
beats/minute (P<0.05). Systolic blood pressure increased after intubation from  
 106.8 ± 3.1 to 121.0 ± 4.4 mm Hg in patients given magnesium and from 106.4 
± 3.12 to 145.1 ± 5.6 mm Hg in the control group (P<0.05). Norepinephrine 
levels increased from 297.3 ± 20.9 pg/ml to a peak of 532.5 ± 30.1 pg/ml 2 
minutes after intubation in the magnesium group. In controls, norepinephrine 
levels increased from 273.3 ± 39.1 mg/ml to 944.6 ± 68.7 pg/ml (P<0.05 for 
differences between groups). Epinephrine levels were unchanged from baseline 
after magnesium but in controls increased from 113.9 ± 19.5 to 279.6 ± 92.3 
pg/ml (P<0.05) . The study concluded that magnesium sulphate attenuates the 
catecholamine mediated responses after tracheal intubation. 
 
13)Gozdemir 
39
 et al, had conducted a study to evaluate whether magnesium 
sulphate infusion during surgery reduces shivering during spinal anesthesia in 
patients coming for Transurethral resection of prostate(TURP) surgeries. Two 
groups were divided, both groups received 3 ml of bupivacaine intrathecally and 
one group received a bolus of 80 mg/kg over 30 min period followed by 2 g/hr 
infusion during the intraoperative period and the other group received equal 
amounts of normal saline. Shivering was significantly reduced in the 
magnesium group (p=0.001). 
   
 
 
 
 
 AIM OF THE STUDY 
 
To evaluate the role of Magnesium sulphate as an adjuvant in accelerating the 
onset of action of injection Bupivacaine in epidural anesthesia in patients 
coming for lower abdominal surgeries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
 
After approval of the study by our institutional ethics committee, the study was 
conducted in 50 ASA grade I or II patients undergoing elective lower abdominal 
surgeries under epidural anaesthesia.  
The age, weight, and height, vital parameters like pulse rate, blood pressure, 
baseline investigations like hemoglobin, blood sugar, urea, creatinine, CXR and 
ECG were all checked. Thorough examination of all the systems and airway 
assessment was done. 
 
INCLUSION CRITERIA: 
 Patients between the age group 18 to 60 yrs 
 Patients in ASA I and II physical status 
 Patients with BMI < 30 kg/m2  
 Patients coming for elective surgeries 
 Patients who have given valid informed consent 
 
EXCLUSION CRITERIA: 
 
 Patients with coagulation abnormality 
 Patients with cardiac or renal failure 
 Patients with mental illness 
 Patients with neurological illness 
 Patients with spinal deformities 
 Patients with allergy to local anesthetics 
 Patients coming for emergency surgeries 
 Patients not fitting into inclusion criteria 
The patients who fulfilled the above explained criteria were taken into the study 
after obtaining written informed consent from them. 
 
MATERIALS USED: 
 18 G or 16 G, 9 cm Tuohy needle, with a 15-20 degrees angulation at the 
tip (Hueber’s tip), filter. 
 18 G epidural catheter 
 5 ml syringe (for LOR ) 
 2 ml syringe 
 local anesthetic preparation of 1.5 % lignocaine with 1 in 2 lac adrenaline 
 
Visual Analog Scale (VAS) was explained to the patients. The patients were 
shown a 10 cm long scale marked 0 – 10 on a blank paper and told that 0 
represented ―no pain‖ and 10 represented ―worst possible pain‖. Rectus 
Abdominis Muscle score was also explained to the patients. A score of 60 % 
represented adequate blockade. 
The patients were randomly allocated into two groups of 25 each by using 
closed envelop method. 
 
 
 
GROUP A: 
Patients received 14 ml of 0.5% Bupivacaine + 1ml of 0.9% Normal saline. 
 
 
GROUP B: 
Patients received 14 ml of 0.5%Bupivacaine +1ml of 50 mg Magnesium 
sulphate. 
 
The total volume of the injected solution was 15 ml in both groups. In the 
operating room, appropriate equipment for airway management and emergency 
drugs were kept ready. Patients were shifted to the operating room. The 
horizontal position of the operating table was checked and the patients were 
positioned. Non-invasive blood pressure monitor, pulse oximeter and ECG 
leads were connected to the patient.  
 
Preoperative baseline systolic and diastolic blood pressure, pulse rate, 
respiratory rate and oxygen saturation were recorded. Patients were cannulated 
with 18G intravenous cannula and preloaded with 1000 ml of crystalloid 
solution.  The patients were placed in sitting position. The skin over the back 
was prepared with antiseptic solution and draped with sterile towel.    T 9 – T 10 
or the T 10 – T 11 interspace was chosen for performing the epidural blockade.  
After infiltrating the skin with local anesthetic, 18 G tuohy needle was inserted. 
The epidural space was identified by loss of resistance technique using the LOR 
syringe. Catheter was threaded cephalad and was placed at a length of 4 to 5 cm 
in the epidural space. A test dose of 3 ml of 1.5% lignocaine with adrenaline 
(1:2, 00,000) was given through the epidural catheter. After ruling out 
intrathecal, intravascular, subdural placement and ensuring the catheter being  
 
 
placed in the epidural space the catheter was fixed in situ. The test drug was 
given and following parameters were monitored. 
 
ONSET OF SENSORY BLOCK: 
The onset of sensory block was defined as the time between the injection of 
anaesthetic solution and the absence of pain at the T6 dermatome. Sensory 
block was assessed by loss of sensation to pinprick by VAS scoring using 22G 
sterile needle bilaterally along the midclavicular line. Sensory blockade was 
checked every 5 mins until T6 dermatome was blocked and also the peak 
sensory blockade level was noted. The duration of sensory block was defined as 
the time for regression of two segments from the maximum block height and 
was evaluated by pin prick. Sensory blockade was checked every 15 mins till 
two segment regression level reached. 
 
VAS SCORE: 
0 – DOES NOT HURT 
2 – HURTS JUST A LITTLE BIT 
4 – HURTS A LITTLE MORE 
6 – HURTS EVEN MORE 
8 – HURTS A LOT 
10 – HURTS AS MUCH AS U CAN IMAGINE 
Time to achieve Score of 0 at T6 was taken as the time for onset of sensory 
blockade. 
 
 
MOTOR BLOCK: 
Motor block was assessed using two scores. The scoring system used was RAM 
(Rectus Abdominis Muscle). This test is employed for assessing the motor 
blockade levels above T12. The other test is the BROMAGE scoring system for 
assessing the motor blockade below L 1. 
 
TIME TO REACH MOTOR BLOCK: 
BROMAGE - 0 – no motor block 
BROMAGE - 1 – inability to raise extended legs  
BROMAGE - 2 – inability to flex knees 
BROMAGE - 3 – inability to flex ankle joint. 
 
RAM TEST
 5
: 
100% – able to rise from supine to sitting with hands behind head 
80%   – sit only with arms extended 
60%   – can lift only head and scapula 
40%   - can lift shoulders only off bed 
20%   - an increase in abdominal muscle tone can be felt during effort, no other 
response. 
A RAM score of 40% to 60% was considered adequate to proceed with the 
surgery. Time taken for obtaining 60 % was taken as the duration of onset for 
motor blockade. 
The surgery was commenced after obtaining the sensory blockade of  level T6 
and motor blockade of 60%. 
 
VITAL SIGNS: 
After performing the blockade, the systolic blood pressure, diastolic blood 
pressure, heart rate, SpO2, respiratory rate were recorded once in every 5 mins 
till the level of two segment regression was reached and monitoring was 
continued throughout the procedure. Patients were shifted to post anesthetic 
care unit and the vital signs were monitored every 15 mins for the first 2 hours 
and then half hourly for 2 hours and every hour for the next 3 hours. Patients 
were then shifted to Post-operative ward after obtaining a bromage score of 0. 
 
SIDE EFFECTS: 
 
Hypotension was defined as fall in systolic blood pressure to more than 30 % its 
baseline value. It was managed with i.v.fluids and with incremental doses of 
Inj.Ephedrine 6 mg i.v. 
 
Bradycardia was defined as fall in heart rate < 60 /min and was managed with 
Inj.Atropine 0.6 mg i.v. Tachycardia was defined as HR > 100/ min and was 
planned to manage the cause. 
 
Respiratory depression was defined as respiratory rate < 8/min or SpO2 < 85% 
and was planned to manage with mask ventilation,intubation and IPPV as per 
the requirement.  
Vomiting was managed with Inj.Ondansetron 8 mg intravenously. 
 
 
After the wearing of analgesic effect of the initial dose, 7 to 10 ml of 2% 
Lignocaine was supplemented in the epidural route for the continuation of the 
surgery. 
 
Shivering was managed with administrations of warm i.v.fluids and covering 
the patient with warm towels. 
 
TIME FOR TWO SEGMENT REGRESSION: 
 
The duration of two segment regression was defined as the time taken for the 
sensory block to regress from the maximum level of blockade to two segments 
down. This time was taken as time for the first epidural top up and was 
supplemented with local anesthetics of half or one third of the initial dose with 
NO supplemental doses of magnesium sulphate. 
 
PROBLEMS IN EPIDURAL BLOCKADE
5
: 
 
Problem in epidural blockade was defined as inability to obtain adequate 
sensory blockade and motor blockade within the segmental area within 30 
minutes of giving the TEST drug in the epidural route. No supplemental doses 
were given. These patients were converted to general anesthesia with tracheal 
intubation and IPPV. 
 
All recorded datas were analysed with SPSS software for Windows Version 
15.0. The quantitative datas were analysed by students t-test and the qualitative 
data by chi-squared test. Power analysis was calculated using Minitab for 
windows and the power was well above the accepted level of 80%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 OBSERVATION & ANALYSIS 
 
This prospective randomised, comparative, double blinded case control study  
evaluates the effect of Magnesium sulphate in accelerating the onset of action of  
bupivacaine in epidural anesthesia in 50 patients coming for lower abdominal  
surgeries. 
 
Results were expressed as mean and standard deviation. All statistical analysis  
were carried out using SPSS for windows version 15.0. The t-test was used for 
          comparison of quantitative variants. A p value of less than 0.05 was considered 
statistically significant. 
 
TABLE 1: Demographic Profile-AGE  
GROUP No. Mean SD P VALUE 
A 25 39.08 12.622 0.738 
Not 
significant 
B 25 40.20 10.813 
 
The age distribution in group B was from 22 to 58 yrs and in group A was 21 to 
59 yrs. The mean age and age distribution in both groups were similar and 
comparable. 
 
 
 
 TABLE 2: Demographic Profile-SEX 
GROUP 
MALE FEMALE P value 
NO % NO % 1.000 
Not 
significant 
A 20 80.0 5 20.0 
B 20 80.0 5 20.0 
 
Of the 50 patients, 40 were males and 10 were females. The distribution was 
similar and comparable in both groups of patients. 
 
TABLE 3: Demographic Profile-BMI 
Group NO Mean SD P value 
A 25 23.19 1.678 0.375 
Not 
significant 
B 25 22.63 2.968 
 
The mean BMI of group A is 23.19 and group B is 22.63. 
The data is statistically not significant (p>0.05) and this both groups are 
comparable in terms of BMI. 
 
TABLE 4: Demographic Profile-ASA PS Status 
GROUP 
ASA I ASA II P value 
NO % NO % 0.082 
Not 
significant 
A 20 80.0 5 20.0 
B 24 96.0 1 4.0 
In group A 20 patients were ASA I and 5 were ASA II patients. In group B 24 
patients were in ASA I and 1 was ASA II patient.  
The data is statistically not significant (p>0.05) and this both groups are 
comparable in terms of ASA PS Status. 
 
TABLE 5: ONSET OF SENSORY & MOTOR BLOCKADE: 
 GROUP NO MEAN SD P value 
Onset of Sensory Block 
A 25 17.80 2.533 <0.001 
significant B 25 11.20 2.179 
Onset of 
Motor Block 
 
A 25 23.60 3.391 
<0.001 
significant B 25 13.80 2.986 
 
In group B the mean time for onset of action of sensory block is 11.20 minutes 
compared to 17.80 minutes in group A. This data is statistically significant by 
Students t-test. 
In group B the mean time for onset of action of motor blockade is 13.80 minutes 
against 23.60 minutes in group A. This data is statistically significant by 
Students t-test. 
 
TABLE 6: TIME FOR TWO SEGMENT REGRESSION: 
GROUP NO MEAN SD P value 
A 25 51.00 7.500 
<0.001 
significant B 25 84.00 7.500 
 
The mean time for two segment regression in group B is 84.00 minutes against 
51.00 minutes in group A.  
Statistical analysis is done using Student t- test. It reveals a P value of <0.001 
which is statistically significant. 
 TABLE 7: HEART RATE: 
HR GROUP NO Mean SD P value 
Baseline 
A 25 89.32 11.957     0.906 Not      
significant B 25 89.72 11.936 
5 MINS 
A 25 82.76 7.224 0.047 
significant B 25 77.84 9.647 
10 MINS 
A 25 76.68 8.081 0.216 Not 
significant B 25 73.84 7.941 
15 MINS 
A 25 73.48 6.893 0.436 Not 
significant B 25 71.76 8.521 
20 MINS 
A 25 73.04 7.300 0.750 Not 
significant B 25 72.36 7.675 
25 MINS 
A 25 71.96 7.408 0.879 Not 
significant B 25 71.64 7.348 
30 MINS 
A 25 73.60 8.475 0.558 Not 
significant B 25 72.20 8.292 
35 MINS 
A 25 72.48 8.559 0.606 Not 
significant B 25 71.12 9.926 
40 MINS 
A 25 71.08 9.699 0.617 Not 
significant B 25 72.40 8.836 
45 MINS 
A 25 72.48 9.980 0.043 
significant B 25 78.24 9.641 
50 MINS 
A 25 76.28 10.730 0.783 Not 
significant B 25 75.36 12.639 
55 MINS 
A 25 77.80 9.713 0.200 Not 
significant B 25 74.28 9.454 
60 MINS 
A 25 76.88 9.506 0.138 Not 
significant B 25 72.96 8.876 
65 MINS 
A 25 76.32 8.654 0.068 Not 
significant B 25 71.28 10.338 
70 MINS 
A 25 74.72 7.706 0.826 Not 
significant B 25 74.12 11.189 
75 MINS 
A 25 74.48 8.714 0.778 Not 
significant B 25 75.20 9.201 
80 MINS 
A 25 74.72 8.116 0.062 Not 
significant B 25 70.52 7.394 
85 MINS 
A 25 75.04 8.085 0.126 Not 
significant B 25 70.84 10.796 
90 MINS 
A 25 74.92 7.863 0.641 Not 
significant B 25 73.80 8.958 
Though the data is statistically significant at 5 and 45 mins both groups are 
comparable in terms of  heart rate with no specific clinical significance.  
 
. 
TABLE 8: SYSTOLIC BLOOD PRESSURE: 
 GROUP N Mean SD P value 
SBP - 
Baseline 
A 25 127.96 9.167 0.114 Not 
significant B 25 124.04 8.008 
SBP - 5 
A 25 113.36 8.261 0.001 
significant B 25 103.56 8.471 
SBP - 10 
A 25 102.72 7.430 0.010 
significant B 25 97.56 6.028 
SBP - 15 
A 25 99.84 6.524 0.471 Not 
significant B 25 101.36 8.169 
SBP - 20 
A 25 102.12 8.536 0.986 Not 
significant B 25 102.16 8.019 
SBP - 25 
A 25 104.12 8.288 0.701 Not 
significant B 25 103.16 9.241 
SBP - 30 
A 25 103.80 9.260 0.390 Not 
significant B 25 106.04 8.988 
SBP - 35 
A 25 107.92 9.522 0.746 Not 
significant B 25 107.16 6.737 
SBP - 40 
A 25 109.64 9.634 0.692 Not 
significant B 25 108.60 8.827 
SBP - 45 
A 25 115.48 12.910 0.023 
significant B 25 108.36 7.926 
SBP - 50 
A 25 114.56 13.690 0.139 Not 
significant B 25 109.76 8.202 
SBP - 55 
A 25 111.32 10.439 0.843 Not 
significant B 25 111.88 9.391 
SBP - 60 
A 25 111.64 7.931 0.319 Not 
significant B 25 114.24 10.183 
SBP - 65 
A 25 113.68 8.260 0.780 Not 
significant B 25 114.32 7.841 
SBP - 70 
A 25 114.68 9.406 0.758 Not 
significant B 25 113.92 7.884 
SBP - 75 
A 25 115.44 8.267 0.974 Not 
significant B 25 115.52 9.038 
SBP - 80 
A 25 116.44 8.347 0.636 Not 
significant B 25 117.60 8.865 
SBP - 85 
A 25 117.32 8.355 0.171 Not 
significant B 25 120.32 6.848 
SBP - 90 
A 25 118.60 7.427 0.015 
significant B 25 124.00 7.719 
Though the data is statistically significant at 5, 10, 45 and 90 mins both groups 
are comparable in terms of Systolic Blood Pressure with no specific clinical 
significance.  
 TABLE 9: DIASTOLIC BLOOD PRESSURE: 
 GROUP N Mean SD P value 
DBP - 
Baseline 
A 25 78.84 8.639 0.059 Not 
significant B 25 73.80 8.986 
DBP - 5 
A 25 73.08 6.910 0.076 Not 
significant B 25 69.52 6.953 
DBP - 10 
A 25 68.08 5.852 0.299 Not 
significant B 25 66.28 6.262 
DBP - 15 
A 25 64.88 5.380 0.092 Not 
significant B 25 62.32 5.129 
DBP - 20 
A 25 62.32 4.039 0.211 Not 
significant B 25 60.88 3.993 
DBP - 25 
A 25 61.68 3.065 0.637 Not 
significant B 25 61.28 2.880 
DBP - 30 
A 25 61.36 3.475 0.400 Not 
significant B 25 60.52 3.513 
DBP - 35 
A 25 61.60 3.440 0.606 Not 
significant B 25 62.20 4.646 
DBP - 40 
A 25 62.36 3.882 0.213 Not 
significant B 25 63.68 3.509 
DBP - 45 
A 25 65.08 5.392 0.092 Not 
significant B 25 67.64 5.139 
DBP - 50 
A 25 68.72 6.141 0.245 Not 
significant B 25 66.88 4.825 
DBP - 55 
A 25 69.12 5.974 0.455 Not 
significant B 25 68.00 4.416 
DBP - 60 
A 25 65.40 4.311 0.520 Not 
significant B 25 64.56 4.848 
DBP - 65 
A 25 61.80 4.082 0.971 Not 
significant B 25 61.84 3.727 
DBP - 70 
A 25 62.12 4.003 0.226 Not 
significant B 25 60.72 4.067 
DBP - 75 
A 25 63.92 4.415 0.034 
significant B 25 67.04 5.623 
DBP - 80 
A 25 61.96 2.835 0.669 Not 
significant B 25 61.64 2.413 
DBP - 85 
A 25 76.44 9.430 0.001 
significant B 25 66.04 5.741 
DBP - 90 
A 25 69.00 6.151 0.116 Not 
significant B 25 66.36 5.484 
Though the data is statistically significant at 75 and 85 mins both groups are 
comparable in terms of  Diastolic  Blood Pressure with no specific clinical 
significance. 
 TABLE 10: MEAN ARTERIAL PRESSURE: 
 GROUP N Mean SD P value 
MAP - 
Baseline 
A 25 95.12 7.463 .052 Not 
significant B 25 90.52 8.058 
MAP - 5 
A 25 86.12 6.180 .001 
significant B 25 79.60 5.260 
MAP- 10 
A 25 78.92 4.481 .026 
significant B 25 75.88 4.842 
MAP- 15 
A 25 75.80 4.233 .344 Not 
significant B 25 74.60 4.628 
MAP- 20 
A 25 75.40 3.841 .376 Not 
significant B 25 74.52 3.084 
MAP- 25 
A 25 75.72 2.851 .187 Not 
significant B 25 74.40 4.021 
MAP- 30 
A 25 74.96 3.208 .177 Not 
significant B 25 76.32 3.794 
MAP- 35 
A 25 76.72 4.430 .786 Not 
significant B 25 76.40 3.830 
MAP- 40 
A 25 77.72 4.929 .653 Not 
significant B 25 78.28 3.736 
MAP- 45 
A 25 81.44 6.965 .716 Not 
significant B 25 80.80 5.276 
MAP- 50 
A 25 83.72 7.254 .034 Not 
significant B 25 79.84 5.121 
MAP- 55 
A 25 83.04 7.168 .534 Not 
significant B 25 81.92 5.354 
MAP- 60 
A 25 79.28 5.683 .468 Not 
significant B 25 80.48 5.924 
MAP- 65 
A 25 79.12 3.140 .874 Not 
significant B 25 79.28 3.889 
MAP- 70 
A 25 79.24 4.512 .402 Not 
significant B 25 78.32 3.038 
MAP- 75 
A 25 80.72 4.421 .123 Not 
significant B 25 82.88 5.278 
MAP- 80 
A 25 79.80 3.240 .860 Not 
significant B 25 79.96 3.142 
MAP- 85 
A 25 89.80 6.494 .001 
significant B 25 83.80 4.387 
MAP- 90 
A 25 84.92 4.932 .842 Not 
significant B 25 85.20 4.916 
Though the data is statistically significant at 5,10, and 85 mins both groups are 
comparable in terms of Mean Arterial Pressure with no specific clinical 
significance. 
 TABLE 11: RESPIRATORY RATE: 
 GROUP N Mean SD P value 
RR - Baseline 
A 25 14.24 0.597 0.86 
Not significant B 25 14.2 0.645 
RR - 5 
A 25 13.96 0.731 0.129 
Not significant B 25 14.4 0.645 
RR-10 
A 25 13.96 0.789 0.130 
Not significant B 25 14.28 0.678 
RR-15 
A 25 13.76 0.663 0.833 
Not significant B 25 14 0.778 
RR-20 
A 25 13.76 0.778 1.000 
Not significant B 25 13.76 0.9 
RR-25 
A 25 13.24 0.879 0.750 
Not significant B 25 13.32 0.723 
RR-30 
A 25 13.56 0.820 0.365 
Not significant B 25 13.76 0.623 
RR-35 
A 25 13.36 0.568 0.650 
Not significant B 25 13 0.577 
RR-40 
A 25 13.4 0.645 0.255 
Not significant B 25 13.72 0.458 
RR-45 
A 25 13.48 0.770 0.188 
Not significant B 25 13.76 0.925 
RR-50 
A 25 13.52 0.871 0. 350 
Not significant B 25 14.08 0.812 
RR-55 
A 25 13.96 0.934 0.630 
Not significant B 25 14.01 0.816 
RR-60 
A 25 13.64 0.568 0.077 
Not significant B 25 14 0.707 
RR-65 
A 25 13.76 0.925 0.308 
Not significant B 25 13.92 0.571 
RR-70 
A 25 14.8 0.571 1.000 
Not significant B 25 14.08 0.568 
RR-75 
A 25 13.72 0.541 0.612 
Not significant B 25 13.96 0.4 
RR-80 
A 25 13.92 0.493 1.000 
Not significant B 25 13.92 0.483 
RR-85 
A 25 13.84 0.687 0.163 
Not significant B 25 13.56 0.351 
RR-90 
A 25 13.88 0.331 0.411 
Not significant B 25 13.96 0.358 
The data is statistically not significant (p>0.05) and this both groups are 
comparable in terms Respiratory Rate. There was no incidence of respiratory 
depression in both the groups. 
 TABLE 12: SPO2 : 
 GROUP N Mean SD P value 
SPO2 - 
Baseline 
A 25 98.52 0.509 0.40 
Not significant B 25 98.64 0.48 
SPO2 -5 
A 25 98.44 0.506 0.263 
Not significant B 25 98.24 0.723 
SPO2 -10 
A 25 98.56 0.506 0.572 
Not significant B 25 98.64 0.48 
SPO2-15 
A 25 98.56 0.506 0.225 
Not significant B 25 98.36 0.637 
SPO2-20 
A 25 98.48 0.506 0.579 
Not significant B 25 98.64 0.48 
SPO2-25 
A 25 98.56 0.506 0.572 
Not significant B 25 98.53 0.489 
SPO2-30 
A 25 98.64 0.48 0.332 
Not significant B 25 98.34 0.653 
SPO2-35 
A 25 98.44 0.506 0.068 
Not significant B 25 98.36 0.068 
SPO2-40 
A 25 98.44 0.506 0.162 
Not significant B 25 98.64 0.48 
SPO2-45 
A 25 98.36 0.506 0.601 
Not significant B 25 98.45 0.583 
SPO2-50 
A 25 98.64 0.48 0.019 
Not significant B 25 98.45 0.583 
SPO2-55 
A 25 98.45 0.506 1.00 
Not significant B 25 98.56 0.506 
SPO2-60 
A 25 98.6 0.5 0.119 
Not significant B 25 98.36 0.568 
SPO2-65 
A 25 98.56 0.48 0.782 
Not significant B 25 98.52 0.509 
SPO2-70 
A 25 98.72 0.458 0.380 
Not significant B 25 98.6 0.5 
SPO2-75 
A 25 98.72 0.458 0.086 
Not significant B 25 98.48 0.509 
SPO2-80 
A 25 98.72 0.458 0.158 
Not significant B 25 98.48 0.509 
SPO2-85 
A 25 98.52 0.509 0.40 
Not significant B 25 98.64 0.48 
SPO2-90 
A 25 98.48 0.509 1.00 
Not significant B 25 98.48 0.48 
The data is statistically not significant (p>0.05) and this both groups are 
comparable in terms of SPO2. 
 
 TABLE 13: CONVERSION TO GENERAL ANESTHESIA: 
 
 Group No Yes % No % P value 
Conversion to 
GA 
A 25 2 8.0 23 92.0 1.000 
Not significant B 25 2 8.0 23 92.0 
 
The incidence of conversion to general anaesthesia is same, 8% in both the 
groups. Statistical analysis using chi square test reveals P value of 1.000, which 
is not significant. 
 
TABLE 14: SIDE EFFECTS: 
 
COMPLICATION Group No Yes % No % P value 
Nausea/Vomiting 
A 25 2 8.0 23 92.0 1.000 
Not significant 
 
B 25 2 8.0 23 92.0 
Hypotension 
A 25 2 8.0 23 92.0 0.637 
Not 
significant 
B 25 3 12.0 22 88.0 
Bradycardia 
A 25 1 4.0 24 96.0 
1.000 
Not 
significant 
B 25 1 4.0 24 96.0 
Shivering 
 
 
A 25 8 32.0 17 68.0 
0.002 
significant 
B 25 0 - 25 100 
Respiratory 
Depression 
A 25 0 - 25 100 
Not 
significant 
B 25 0 - 25 100 
 
The incidences of nausea/vomiting, hypotension, bradycardia, respiratory 
depression are comparable in both the groups. Statistical analysis is done using 
chi square test. 
The incidence of shivering is 32% in group A vs 0% in group B. Chi square test 
reveals a P value of 0.002 which is statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DISCUSSION 
 
The primary aim of the study was to evaluate the effect of adding magnesium 
sulphate with bupivacaine in accelerating the onset of action for epidural 
anesthesia in patients coming for lower abdominal surgeries. The safety of 
adding magnesium sulphate in epidural route has been witnessed in previously 
done studies in humans by TANMOY et al 
8
, A.BILIR et al
 9
,S.FAROUK 
10
. 
in the studies done by the above authors the dosage of magnesium sulphate used 
was 50 mg.  
 
There are studies done in evaluating the effect of magnesium sulphate in spinal 
anesthesia by M.OZALEVLI et al 
13
, ASOKKUMAR BUVENDRAN et al
14
 
and JONG WHA LEE et al
15
. The dosage of magnesium sulphate used in 
these studies was 50 mg magnesium sulphate which showed no deleterious 
effect in humans. 
 
There are studies done by J.Y.HWANG et al 
24
, T.O.SEYHAN et al 
31
, 
N.M.ELSARHOUBY et al 
32
 and many others were magnesium sulphate being 
evaluated at a dosage of 50 mg per kg intravenously with absolutely no 
complications. 
 
 
 
 SENSORY & MOTOR BLOCKADE: 
 
In this study, the time for sensory blockade was 11.20 ± 2.179 in the 
Magnesium group (B) and 17.80 ± 2.533 in the control group (A) with a p value 
of <0.001 which showed statistical significance of early onset in the magnesium 
group. 
 
The time for two segment motor regression 84.00 ± 7.5 in the magnesium group 
and 51.00 ± 7.50 in the control group with a p value of <0.001 which showed 
statistical significance of prolonged action in the magnesium group. 
 
The above values of this study correlates with the study done by TANMOY
8
 et 
al in which the onset of sensory blockade to in Magnesium Group 11.80 ± 3.21 
minutes and in the control group it was 18.73 ± 2.79 minutes. The time for two 
segment regression was prolonged in the magnesium group and was found to be 
statistically significant. 
 
The onset of action of this study correlates with the study done by TANMOY
8
 
et al, while the time for two segment regression was soon in this study. 
However this can be explained with the volume of Bupivacaine used in the 
study done by TANMOY et al
8
 was more than this study. 
 
The other studies done by BILIR
9
 et al, FAROUK
10
 et al support the analgesic 
effect of magnesium sulphate used in epidural route. 
 SIDE EFFECTS: 
The incidence of nausea and vomiting was similar in both the groups . 
The incidence of hypotension was similar in both the groups. 
The incidence of bradycardia was similar in both the groups. 
The incidence of shivering was reduced in the magnesium group with a p value 
<0.002. this finding correlates with the studies done by TANMOY et al 
8
 and 
GODZEIMER et al 
39  
The incidence of respiratory depression was similar in both the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
 
We conducted a randomised double blinded control study in a group of 50 
patients belonging to ASA I and II undergoing elective lower abdominal 
surgeries to evaluate the effect of adding magnesium sulphate with injection 
bupivacaine in epidural anesthesia. Two groups of 25 each were randomly taken 
and analysed. The groups were comparable in terms of demographic profile. 
 
The purpose of the study was to determine the time for onset of action of 
sensory and motor blockade. Data showed statistical significance of early onset 
of action in the magnesium group. 
 
On the course of the study the time taken for two segment regression from the 
peak sensory level was found to be prolonged in the magnesium group. The 
obtained data showed statistical significance. 
 
Also on the due course of the study it was found that the incidence of shivering 
was less in the patients belonging to the magnesium group compared to the 
control group which showed statistical significance. 
 
Also epidural magnesium did not produce significant side effects in the study. 
 
 
 CONCLUSION 
 
This study concludes that addition of epidural magnesium sulphate accelerates 
the onset of action of epidural bupivacaine and also prolongs the duration of 
action of epidural bupivacaine in patients coming for lower abdominal surgeries 
without increasing the incidence of side effects. 
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PATIENT CONSENT FORM 
 
Study title  : To evaluate magnesium sulphate in accelerating the onset of action of 
injection bupivacaine used for epidural anaesthesia 
                                                                        
Study centre :                  Institute of Anaesthesiology & Critical care, 
                                        Madras Medical College. 
 
Participant name :                                    Age:                          
O.P.No:                                                    Sex:                                 
 
                        I confirm that I have understood the purpose of procedure for the above study . 
I have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. 
                      
                        I have been explained about the pitfall in the procedure and in that case 
anaesthesia can be accomplished through general anaesthesia .  I have been explained about 
the safety, advantage and disadvantage of the technique. 
 
                        I understand that my participation in the study is voluntary and that i am free 
to withdraw at anytime without giving any reason. 
 
                        I understand that investigator ,regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to current study and 
any further research that may be conducted in relation to it, even if I withdraw from the study 
. I understand that my identity will not be revealed in any information released to third parties 
or published , unless as required under the law . I agree not to restrict the use of any data or 
results that arise from the study . 
 
                        I hereby consent to participate in this study To evaluate magnesium 
sulphate in accelerating the onset of action of injection bupivacaine used for epidural 
anaesthesia 
 
Time:          
 
Date:                                                                 signature / thumb impression of patient  
                                  
 
Place:                                                                 patient name: 
 
Signature of the investigator: 
 
Name of the investigator: 
 
  
PROFORMA 
STUDY TO EVALUATE MAGNESIUM SULPHATE IN ACCELERATING THE 
ONSET OF ACTION OF INJECTION BUPIVACAINE USED FOR EPIDURAL 
ANAESTHESIA 
 
NAME :                                                    AGE:                 SEX:                  I.P.No:  
DIAGNOSIS:                                                                      SURGERY  PLANNED:  
PREOPERATIVE ASSESSMENT:  
HISTORY:  
CO-MORBID ILLNESS & TREATMENT DETAILS:  
 EFFORT TOLERANCE- _______ METS 
 H/O PREVIOUS SURGERY : 
GENERAL EXAMINATION:  
HEIGHT:                                      WEIGHT:                      BMI: 
 ANAEMIA-                                  JAUNDICE-                  SPINE-                  
PULSE-                                          BP-                               CVS-                                        RS- 
INVESTIGATIONS: 
Hb :                                              BT:                                 CT:                                            
BLOOD GROUPING&TYPING: 
BLOOD SUGAR:                          UREA:                           CREATININE: 
ECG:                                             CXR: 
 
EPIDURAL BLOCKADE: 
 
SPACE 
 
NEEDLE 
 
SIZE 
 
APPROACH 
 
POSITION 
 
TIME 
 
DRUG 
       
 
SENSORY BLOCK & MOTOR BLOCK:                                                                                      
 LEVEL TIME 
SENSORY   
MOTOR   
 
 
 
PEAK SENSORY BLOCKADE: 
SENSORY BLOCK: 
VAS SCORE: 
0 – DOES NOT HURT 
2 – HURTS JUST A  LITTLE BIT 
4 – HURTS A LITTLE MORE 
6 – HURTS EVEN MORE 
8 – HURTS A LOT 
10 – HURTS AS MUCH AS U CAN IMAGINE 
MOTOR BLOCK: 
TIME TO REACH MOTOR BLOCK  : 
BROMAGE - 0 – no motor block 
BROMAGE - 1 – inability to raise extended legs  
BROMAGE - 2 – inability to flex knees 
BROMAGE - 3 – inability to flex ankle joints 
RAM TEST: 
100% – able to raise from supine to sitting with hands behind head 
80%   – sit only with arms extended 
60%   – can lift only head and scapula 
40%   - can lift shoulders only off bed 
20%   - an increase in abdominal muscle tone can be felt during effort, no other response 
INTRA OP VITAL PARAMETERS: 
TIME PR SBP DBP MAP SpO2 RR SIDE 
EFFECTS 
Base line        
5 min        
10 min        
15min        
20min        
25min        
30min        
35min        
40min        
45min        
50min        
55min        
60min        
65min        
70min        
75min        
80min        
85min        
90min        
 
SIDE EFFECTS : 
 
Side effects 
 
 
Nausea / vomiting 
 
 
Hypotension 
 
 
Bradycardia 
 
 
Shivering 
 
 
Need for intra op analgesia 
 
 
Respiratory depression 
 
INTRA OP EVENTS:   
IV FLUIDS : 
 
INJ.EPHEDRINE  :     DOSE               TIME        
 
INJ.ATROPINE (0.6 mg iv bolus) : 
CONVERSION TO GA :  
TIME FOR FIRST TWO SEGMENT REGRESSION (IN MINS): 
 
 
S.NO NAME AGE GROUP SEX I.P.NO. ASA 
BM
I 
ONSET OF   
SENSORY 
BLOCKAD
E IN 
MINUTES 
ONSET OF 
MOTOR 
BLOCKAD
E  IN 
MINUTES 
TIME FOR 
TWO 
SEGMENT 
REGRESSI
ON IN 
MINUTES 
PEAK 
SENSORY 
BLOCKAD
E 
RAMSA
Y 
SEDATI
ON 
SCORE 
CONV
ERSIO
N TO 
GA 
NAUSE
A/VOM
ITING 
HYPO
TENSI
ON 
BRADY
CARDIA 
SHIV
ERIN
G 
RESPIRA
TORY 
DEPRESSI
ON 
1 ARUMUGAM 25 A M 73839 1 21.6 15 20 45 T6 2 NO NO NO NO NO NO 
2 PUNITHA 48 A F 73522 2 22.5 15 25 45 T6 2 NO YES NO NO YES NO 
3 RAJAVEL 18 A M 74567 1 26.5 15 20 45 T6 2 NO NO NO NO YES NO 
4 ARJUN 40 A M 74959 1 21.5 20 25 60 T6 2 NO NO NO NO YES NO 
5 KUMAR 52 A M 73412 2 20.4 20 25 45 T6 2 YES NO NO NO NO NO 
6 VARALAKSHMI 35 A F 73487 1 22.2 20 25 45 T6 2 NO NO NO NO NO NO 
7 RAMACHANDRAN 59 A M 71344 2 24.9 15 20 45 T4 2 NO NO NO NO YES NO 
8 CHINAYAN 50 A M 73376 1 21.5 20 20 60 T6 2 NO NO NO NO NO NO 
9 THANGARAJ 58 A M 72052 2 23.5 15 20 60 T6 2 NO YES YES NO YES NO 
10 RAVI 35 A M 75541 1 23.3 20 20 60 T6 2 NO NO NO NO NO NO 
11 SUSEELA 58 A F 71414 2 24.1 20 25 45 T4 2 NO NO NO NO NO NO 
12 VIJAYAKUMAR 23 A M 75943 1 22.8 15 20 45 T4 2 NO NO NO NO NO NO 
13 PRAKASH 25 A M 75800 1 21.9 15 20 45 T6 2 NO NO NO NO NO NO 
14 KARTHIKEYAN 32 A M 75160 1 22 20 20 60 T6 2 NO NO NO NO YES NO 
15 SHANTHI 49 A F 75797 1 23.4 20 25 45 T4 2 YES NO NO NO YES NO 
16 KARUNAKARAN 50 A M 77254 1 26 20 25 60 T6 2 NO NO NO NO NO NO 
17 VENDA 35 A F 71111 1 22.4 20 20 45 T6 2 NO NO NO NO YES NO 
18 MURUGAN 25 A M 75943 1 25 20 25 45 T4 2 NO NO NO NO NO NO 
19 ELUMALAI 25 A M 71325 1 21.1 15 25 45 T6 2 NO NO NO NO NO NO 
20 MARIMUTHU 48 A M 77542 1 23.7 20 25 45 T6 2 NO NO YES NO NO NO 
21 VARADHARAJAN 45 A M 76139 1 21.3 15 25 60 T6 2 NO NO NO NO NO NO 
22 ARUMUGAM 49 A M 77957 1 23.6 15 25 45 T6 2 NO NO NO NO NO NO 
23 NARESHKUMAR 27 A M 72154 1 24.6 20 30 60 T6 2 NO NO NO YES NO NO 
24 RAMAN 40 A M 79201 1 27.3 20 30 60 T6 2 NO NO NO NO NO NO 
25 SIVA 26 A M 77281 1 23.5 15 30 60 T6 2 NO NO NO NO NO NO 
S.NO NAME AGE GROUP SEX I.P.NO. ASA 
BM
I 
ONSET OF   
SENSORY 
BLOCKAD
E IN 
MINUTES 
ONSET OF 
MOTOR 
BLOCK IN 
MINUTES 
TIME FOR 
TWO 
SEGMENT 
REGRESSI
ON IN 
MINUTES 
PEAK 
SENSORY 
BLOCKAD
E  
RAMSA
Y 
SEDATI
ON 
SCORE 
CONV
ERSIO
N TO 
GA 
NAUSE
A/VOM
ITING 
HYPO
TENSI
ON 
BRADY
CARDIA 
SHIV
ERIN
G 
RESPIRA
TORY 
DEPRESSI
ON 
1 KANNAN 36 B M 77567 1 22.2 10 10 75 T4 2 NO YES YES NO NO NO 
2 RAJENDRAN 40 B M 77537 1 23.4 10 15 90 T4 2 NO NO NO NO NO NO 
3 RAJKUMAR 20 B M 79397 1 25.1 10 15 75 T4 2 NO NO NO NO NO NO 
4 ALAGRAH 40 B M 78498 1 21.9 10 15 90 T4 2 YES NO NO YES NO NO 
5 MUTHUSAMY 26 B M 78651 1 22.4 15 15 75 T6 2 NO NO NO NO NO NO 
6 KARPAGAM 45 B M 77984 1 22.3 10 15 75 T6 2 NO NO NO NO NO NO 
7 CHINNAPPA 51 B M 77690 1 21.6 10 10 90 T6 2 NO NO NO NO NO NO 
8 ARUNACHALAM 57 B M 76011 1 24.5 10 15 75 T6 2 NO NO NO NO NO NO 
9 PRAKASH 35 B M 78331 1 21.5 10 15 75 T4 2 NO NO NO NO NO NO 
10 VEDHAM 59 B F 76848 2 22.8 10 15 90 T4 2 NO NO YES NO NO NO 
11 ANNAMALAI 43 B M 77541 1 23.4 10 15 75 T6 2 NO NO NO NO NO NO 
12 ROSY 24 B F 78341 1 26.5 10 10 90 T6 2 NO YES YES NO NO NO 
13 SURESHBABU 35 B M 76402 1 21 10 15 75 T6 2 NO NO NO NO NO NO 
14 DEVI 20 B F 79118 1 9 15 15 90 T6 2 NO NO NO NO NO NO 
15 SARAVANNAN 42 B M 79896 1 20.9 15 15 90 T6 2 NO NO NO NO NO NO 
16 PERUMAL 43 B M 70597 1 24.1 15 15 90 T6 2 NO NO NO NO NO NO 
17 SHANTHI 47 B F 80780 1 25 10 10 75 T6 2 NO NO NO NO NO NO 
18 GOVARDHAN 48 B M 79576 1 23.8 10 10 90 T6 2 NO NO NO NO NO NO 
19 JAGANATHAN 40 B M 79807 1 23.7 10 10 90 T6 2 NO NO NO NO NO NO 
20 SHANTHI 46 B F 78773 1 24.6 10 10 90 T6 2 NO NO NO NO NO NO 
21 GOWTHAMAN 24 B M 81999 1 22.5 15 20 90 T6 2 YES NO NO NO NO NO 
22 AYYANAR 40 B M 79542 1 22.8 10 20 90 T6 2 NO NO NO NO NO NO 
23 MANI 55 B M 79901 1 21.9 10 15 90 T6 2 NO NO NO NO NO NO 
24 ARJUNAN 45 B M 88932 1 20.6 15 10 90 T6 2 NO NO NO NO NO NO 
25 DAYALAN 44 B M 79512 1 26 10 15 75 T6 2 NO NO NO NO NO NO 
  
  
S.NO 
SYSTOLIC BLOOD PRESSURE IN GROUP A (mm Hg) 
BASE 
LINE 
 5 
MINS 
10 
MINS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS  
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85MINS 
90 
MINS 
1 140 126 94 98 92 119 90 102 104 110 126 134 122 125 129 126 122 128 127 
2 136 122 115 101 109 115 118 115 122 136 145 124 121 123 125 122 123 126 121 
3 130 114 112 96 92 102 106 119 118 120 128 102 104 108 107 110 113 114 115 
4 132 119 106 109 106 114 102 104 96 101 103 105 107 109 96 102 104 106 109 
5 130 124 115 108 112 96 90 94 98 95 99 101 106 108 112 116 112 114 119 
6 133 116 101 92 101 104 102 98 99 102 106 100 102 98 101 108 120 122 124 
7 124 100 98 106 102 105 101 104 112 126 139 126 121 123 130 128 126 124 129 
8 110 96 102 101 106 98 94 110 109 129 105 106 104 101 106 110 114 115 122 
9 123 110 106 90 98 90 96 99 119 129 136 107 110 112 116 117 119 121 118 
10 140 112 109 103 105 109 114 118 116 117 114 113 112 110 122 124 126 125 123 
11 126 122 110 103 90 90 126 104 106 109 102 101 103 115 119 122 112 119 120 
12 120 116 101 100 118 112 111 116 122 124 128 125 124 129 127 124 129 123 124 
13 131 105 93 95 120 101 103 107 104 106 109 110 116 112 114 113 120 124 126 
14 130 114 101 90 92 116 101 109 110 125 129 116 110 114 116 120 124 122 120 
15 142 116 96 99 101 100 106 102 108 129 110 112 114 116 113 118 111 110 118 
16 122 106 90 91 92 110 114 117 110 114 112 116 118 117 102 103 106 102 108 
17 124 108 104 98 105 102 103 112 115 119 121 123 124 126 121 124 120 129 122 
18 135 116 101 102 106 102 98 96 91 121 101 103 104 106 109 106 103 108 110 
19 126 101 102 100 94 98 96 126 103 101 102 106 108 109 110 112 111 108 104 
20 110 108 90 91 115 98 92 96 104 90 94 92 101 100 102 98 106 104 102 
21 115 114 106 104 99 92 94 91 101 104 102 101 104 117 114 115 118 122 128 
22 124 113 110 109 101 102 104 110 126 129 119 124 122 121 126 120 127 125 123 
23 118 106 93 92 90 116 115 124 128 135 114 117 120 121 124 126 128 124 121 
24 142 124 112 106 104 102 107 108 104 103 106 104 102 108 109 110 101 104 110 
25 136 126 101 112 103 110 112 117 116 113 114 115 112 114 117 112 116 114 122 
  
S.N
O 
SYSTOLIC BLOOD PRESSURE IN GROUP B (mm Hg) 
BASE 
LINE 
 5 
MINS 
10 
MINS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS  
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85MI
NS 
90 
MINS 
1 119 101 90 98 90 96 99 106 101 104 107 110 112 116 117 119 121 122 129 
2 122 125 103 105 109 114 118 116 117 114 113 112 110 122 124 126 125 122 126 
3 146 104 103 90 90 126 104 106 109 102 101 103 115 119 122 112 119 120 115 
4 114 99 100 118 112 111 116 122 124 128 125 124 129 127 124 129 123 121 123 
5 124 102 95 120 101 103 107 104 106 109 110 116 112 114 113 120 124 127 129 
6 129 104 90 92 116 101 109 110 115 119 116 110 114 116 120 124 122 119 118 
7 119 114 99 101 100 106 102 108 109 110 112 114 116 113 118 111 110 112 114 
8 126 102 91 92 110 114 117 110 114 112 116 118 117 102 103 106 102 116 113 
9 124 101 98 105 102 103 112 115 119 121 123 124 126 121 124 120 129 122 124 
10 122 96 102 106 102 98 96 91 121 101 103 104 106 109 106 103 108 124 129 
11 134 112 100 94 98 96 126 103 101 102 106 108 109 110 112 111 108 116 119 
12 127 101 91 115 98 92 96 104 90 94 92 101 100 102 98 106 126 132 134 
13 126 93 104 99 92 94 91 101 104 102 101 104 117 114 115 118 122 126 132 
14 124 98 109 101 102 104 110 114 116 119 124 122 121 126 120 127 125 122 125 
15 122 91 92 90 116 115 114 112 119 114 117 120 121 124 126 128 124 121 120 
16 118 102 106 104 102 107 108 104 103 106 104 102 108 109 110 101 104 123 136 
17 117 98 90 103 110 112 117 116 113 114 115 112 114 117 112 116 114 112 118 
18 128 94 102 106 110 117 107 105 102 106 108 103 107 108 109 105 104 115 119 
19 126 99 90 92 110 92 94 110 117 112 115 138 145 110 112 114 116 113 128 
20 138 104 92 106 108 102 99 104 109 107 116 121 124 129 121 132 134 140 142 
21 121 118 100 101 99 94 106 108 104 102 101 114 118 119 112 118 127 124 126 
22 124 107 105 94 96 98 99 98 101 98 104 105 98 106 102 104 108 112 118 
23 104 102 96 98 93 94 95 97 92 104 102 98 104 103 101 105 109 116 124 
24 128 121 101 106 98 94 110 109 108 105 106 104 101 106 110 114 115 109 110 
25 119 101 90 98 90 96 99 106 101 104 107 110 112 116 117 119 121 122 129 
S.
NO 
DIASTOLIC BLOOD PRESSURE in Group A (mm Hg) 
BASEL
INE 
5 
MIN
S 
10MI
NS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS  
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 92 88 75 56 58 56 64 62 60 61 62 60 64 60 68 64 63 62 61 
2 86 76 74 69 66 64 70 68 64 69 74 72 68 61 64 62 62 69 64 
3 84 70 62 66 64 62 64 62 63 72 70 74 71 55 63 62 64 66 71 
4 80 73 72 64 68 64 69 62 61 65 68 66 66 60 61 59 68 86 77 
5 76 71 60 76 72 68 63 59 55 59 58 62 68 68 55 61 61 82 69 
6 70 69 64 66 62 61 60 61 60 62 64 68 64 64 60 61 63 79 75 
7 66 66 60 68 64 63 62 61 68 63 69 76 62 58 68 58 60 92 72 
8 69 70 58 64 63 60 60 58 64 66 72 70 74 69 64 54 59 74 68 
9 66 64 66 62 58 59 56 54 58 62 70 74 70 62 58 64 64 66 64 
10 86 80 62 74 66 64 62 64 69 70 69 72 69 68 69 63 63 84 78 
11 82 80 64 70 68 63 61 63 62 65 68 66 60 62 62 69 66 80 72 
12 79 74 74 69 61 66 60 69 68 74 72 75 69 63 68 64 64 66 68 
13 92 70 72 60 58 64 62 64 62 60 64 69 63 64 62 61 58 82 70 
14 74 70 71 69 61 58 63 61 63 64 71 76 62 66 63 62 62 77 80 
15 66 64 68 63 60 62 61 62 64 68 74 70 65 63 64 68 55 74 66 
16 84 78 62 62 59 55 60 68 66 64 68 64 62 59 66 64 61 76 62 
17 80 82 64 56 59 61 61 64 63 66 72 76 64 64 63 66 64 87 67 
18 66 61 71 62 63 64 62 58 59 54 74 72 56 59 59 68 59 96 69 
19 82 64 77 64 60 59 60 59 64 60 63 66 74 54 64 64 62 81 59 
20 77 69 69 56 55 62 59 62 59 62 60 55 64 62 59 62 65 62 79 
21 74 72 75 74 69 65 56 58 54 60 61 62 65 60 54 74 60 60 68 
22 76 74 72 64 61 60 54 58 62 73 78 72 61 61 60 70 58 72 74 
23 87 83 68 65 62 58 60 62 60 78 86 80 62 55 56 69 62 78 72 
24 96 82 64 62 61 62 61 60 62 64 66 63 68 60 62 60 62 83 62 
25 81 77 78 61 60 62 64 61 69 66 65 68 64 68 61 69 64 77 58 
  
S.N
O 
DIASTOLIC BLOOD PRESSURE in Group B (mm Hg) 
BASELI
NE 
5 
MINS 
10MI
NS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS  
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 75 65 68 58 57 59 55 59 62 67 64 63 62 59 54 78 62 67 68 
2 64 60 74 61 64 62 64 61 63 70 69 66 68 64 60 63 58 75 58 
3 87 81 72 69 62 58 68 66 62 68 66 64 60 59 61 62 62 71 59 
4 81 73 62 66 63 62 60 64 61 69 72 70 64 54 64 61 60 68 64 
5 64 62 58 59 61 60 61 65 64 68 66 68 66 62 66 64 64 66 74 
6 61 60 62 57 60 64 63 68 66 71 76 72 64 60 62 68 62 87 75 
7 67 68 64 60 59 62 60 61 63 66 70 71 60 61 55 61 58 66 73 
8 75 64 59 61 54 58 66 64 68 74 73 74 61 55 64 64 60 68 65 
9 71 68 62 60 58 60 64 68 66 71 68 72 63 60 61 69 61 64 66 
10 68 68 60 64 62 61 58 52 51 78 74 71 62 68 66 66 63 58 63 
11 91 78 74 75 70 63 59 69 64 60 62 74 72 64 56 72 62 69 62 
12 87 81 72 73 72 62 54 59 63 56 58 62 61 58 60 66 58 62 72 
13 84 80 64 62 60 58 55 56 61 64 62 68 66 69 60 76 61 68 61 
14 72 73 63 61 62 61 59 64 62 69 70 72 62 62 58 70 66 62 66 
15 74 70 60 54 55 66 64 68 67 72 70 74 64 68 55 73 62 63 62 
16     62 64 68 62 60 62 63 65 64 68 64 68 63 62 64 68 64 64 64 
17 64 61 58 59 62 64 62 67 69 77 72 69 64 63 68 74 63 66 63 
18 86 77 59 61 60 63 61 64 63 68 69 72 68 64 60 62 64 63 64 
19 63 60 64 55 58 64 59 56 66 72 71 71 72 66 61 58 68 59 68 
20 82 79 74 65 64 68 62 54 62 64 66 64 77 63 63 62 60 64 72 
21 78 72 75 69 62 60 61 64 67 66 64 63 74 59 60 70 61 67 77 
22 74 70 73 65 60 61 62 61 64 63 60 62 61 64 66 64 61 62 74 
23 64 63 65 60 58 54 60 58 68 60 61 59 61 60 64 62 60 64 61 
24 76 72 79 64 62 61 58 63 64 63 61 68 57 63 56 65 59 61 60 
25 75 69 68 58 57 59 55 59 62 67 64 63 62 59 54 78 62 67 68 
S.
NO 
MEAN ARTERIAL PRESSURE in Group A (mm Hg) 
BASEL
INE 
5 
MIN
S 
10 
MINS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS 
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 108 100 78 70 69 77 72 73 74 77 83 84 83 83 81 84 82 84 83 
2 102 91 87 79 80 81 82 83 83 90 98 89 85 81 86 82 82 88 83 
3 99 84 78 76 73 75 78 82 81 88 89 83 82 72 77 78 80 82 85 
4 97 88 83 76 80 80 80 78 72 77 79 79 79 76 72 73 80 92 87 
5 94 88 78 78 85 77 72 72 69 71 71 75 80 81 74 79 78 92 85 
6 91 84 76 74 75 75 74 70 73 75 78 78 76 75 73 76 82 93 91 
7 85 77 72 79 76 77 75 76 82 84 92 92 81 79 88 81 82 102 91 
8 82 78 72 76 77 72 71 76 79 87 83 82 84 79 78 72 77 87 86 
9 85 79 79 71 71 70 78 72 78 84 92 85 83 78 81 81 82 84 82 
10 104 90 77 83 79 79 79 74 84 85 84 85 83 82 86 83 84 97 93 
11 96 94 79 82 75 72 76 76 76 79 79 77 74 79 81 86 81 93 88 
12 92 88 83 79 80 81 74 84 86 90 90 91 57 85 88 84 85 85 86 
13 105 81 75 71 78 76 75 78 76 75 79 82 80 80 79 78 78 96 80 
14 92 84 77 76 71 77 74 77 78 88 90 89 78 82 80 81 82 92 93 
15 91 81 77 75 74 74 75 75 78 85 86 84 81 80 80 84 73 86 83 
16 96 87 71 71 70 73 78 84 80 79 82 81 80 78 78 77 76 84 77 
17 94 90 77 70 74 74 77 80 80 82 88 91 84 84 82 85 82 101 85 
18 89 79 81 75 77 76 73 70 69 76 83 82 72 74 75 80 73 100 82 
19 96 76 85 76 71 72 72 82 77 73 76 79 85 77 79 80 78 90 74 
20 88 82 76 67 75 74 70 75 74 71 71 67 76 78 73 74 78 76 86 
21 87 86 85 84 79 74 71 69 69 74 74 65 78 79 74 87 79 80 88 
22 92 87 86 79 76 77 70 75 83 91 91 89 81 81 82 86 81 89 90 
23 103 90 76 74 71 77 78 82 82 97 95 92 81 82 78 88 84 93 88 
24 111 96 80 76 75 75 75 77 76 77 79 92 79 77 77 76 75 90 78 
25 99 93 85 78 74 78 75 78 84 81 81 83 80 76 79 83 81 89 79 
  
 
 
 
 
  
S.
NO 
MEAN ARTERIAL PRESSURE in Group B (mm Hg) 
BASEL
INE 
5 
MIN
S 
10 
MINS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS 
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 99 77 75 71 74 71 78 76 75 79 78 78 79 78 75 91 81 85 88 
2 83 81 77 75 79 79 81 78 81 84 83 81 77 85 81 84 80 90 80 
3 106 86 82 76 70 81 76 76 81 79 77 77 74 79 81 78 81 87 77 
4 92 81 74 83 78 78 78 84 82 88 89 88 88 78 84 83 81 85 83 
5 84 75 70 76 74 74 76 75 78 81 80 84 79 79 81 82 84 86 92 
6 83 74 71 68 78 76 78 76 82 87 74 84 80 78 81 86 82 97 89 
7 84 83 75 73 72 76 77 78 78 80 88 85 81 78 76 77 75 81 86 
8 92 76 69 71 72 74 83 79 83 86 84 86 79 74 77 78 74 84 81 
9 88 79 74 75 72 72 80 76 83 87 86 89 84 81 82 86 83 83 85 
10 86 77 74 78 75 73 70 65 74 85 83 82 75 77 79 78 78 80 85 
11 105 89 84 74 80 74 80 74 76 74 76 85 84 79 74 85 77 84 81 
12 100 87 78 87 80 72 76 75 72 68 69 75 74 77 72 79 80 85 92 
13 98 87 77 74 70 70 67 74 75 76 74 80 83 81 78 90 81 87 84 
14 89 72 78 74 74 75 76 80 80 85 85 85 81 89 78 89 85 82 85 
15 90 77 70 66 75 82 80 82 84 86 78 89 82 85 79 91 82 82 81 
16 80 76 80 76 74 77 78 78 77 80 77 76 78 77 80 79 77 83 88 
17 79 73 68 73 77 80 80 83 83 89 86 77 80 81 81 88 80 81 81 
18 100 75 72 76 76 81 77 76 76 80 82 78 81 78 79 76 77 80 82 
19 84 73 72 67 75 73 78 77 83 85 85 93 96 80 80 76 84 77 88 
20 100 80 76 78 78 70 74 74 77 78 82 89 92 86 82 85 84 89 95 
21 92 87 83 79 74 71 73 78 79 79 76 82 88 81 77 86 83 86 93 
22 90 82 85 74 72 73 72 73 76 74 77 78 73 77 76 77 76 78 88 
23 77 76 75 72 71 67 71 72 72 77 74 72 75 75 76 76 76 81 82 
24 93 88 83 78 73 70 77 77 77 78 76 76 71 78 74 81 77 77 76 
25 89 79 75 71 70 71 72 74 73 75 77 79 78 71 75 91 81 85 88 
                    
S.
NO 
HEART RATE- A GROUP 
BASEL
INE 
 5 
MIN 
10 
MINS 
15MI
NS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS  
50 
MINS 
55 
MINS 
60 
MINS 
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 76 76 72 74 65 60 55 52 60 62 74 69 66 67 66 74 75 60 68 
2 78 79 82 78 74 74 75 78 79 80 86 66 68 65 64 74 70 70 74 
3 87 84 64 66 81 86 83 84 82 76 87 80 87 64 68 65 68 74 72 
4 95 86 67 79 62 65 67 60 56 52 106 87 81 62 69 69 69 82 85 
5 109 87 69 85 71 72 75 74 71 78 110 102 76 75 77 70 63 56 84 
6 101 70 64 75 70 74 75 81 82 85 89 88 90 85 90 81 62 64 68 
7 79 70 71 87 66 64 68 60 56 84 86 80 86 84 73 74 64 74 70 
8 108 66 74 75 71 76 75 74 72 80 66 69 69 60 69 66 67 75 73 
9 79 64 74 70 74 75 81 82 85 84 64 62 60 70 66 68 65 52 60 
10 85 68 65 68 64 68 60 56 84 89 71 76 75 74 80 87 64 78 79 
11 86 69 69 69 75 68 69 64 68 71 74 75 81 82 87 81 62 84 82 
12 103 77 70 63 74 75 81 82 85 84 64 68 60 56 102 76 75 60 56 
13 92 90 81 62 64 68 60 56 84 89 75 68 69 64 88 90 85 74 71 
14 90 73 74 64 75 68 69 64 68 71 72 75 71 74 80 86 84 81 82 
15 101 69 66 67 84 86 74 76 67 75 70 79 78 66 73 71 62 60 56 
16 86 66 68 65 85 80 76 84 72 78 65 60 55 52 60 62 72 74 72 
17 87 80 87 64 84 86 88 89 80 88 74 74 75 78 79 80 70 82 85 
18 106 87 81 62 69 69 60 68 62 79 81 86 83 84 82 76 65 56 84 
19 110 102 76 75 62 60 70 74 72 74 62 65 67 60 56 52 74 64 68 
20 89 88 90 85 70 64 75 70 74 71 71 72 75 74 71 78 81 82 85 
21 86 80 86 84 70 71 87 66 64 84 70 74 75 81 82 85 62 56 84 
22 85 87 78 68 66 74 75 71 76 89 66 64 68 60 56 84 71 64 68 
23 87 85 77 71 64 74 70 74 75 71 71 76 75 74 72 80 70 76 67 
24 74 75 81 82 85 65 68 64 68 95 60 68 62 79 81 86 82 84 72 
25 64 68 60 56 84 69 69 75 68 67 70 74 72 92 62 65 81 89 80 
 
  
S.
NO 
HEART RATE- B GROUP 
BASEL
INE 
 5 
MIN 
10 
MINS 
15MI
NS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS  
50 
MINS 
55 
MINS 
60 
MINS 
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85 
MINS 
90 
MINS 
1 105 90 75 72 78 70 75 71 75 76 74 66 64 66 70 72 79 78 74 
2 82 84 66 70 66 61 84 74 68 62 61 60 86 88 76 74 80 74 75 
3 96 89 82 79 85 84 84 86 74 76 67 65 62 66 75 74 75 82 82 
4 95 84 86 85 90 84 85 80 76 84 72 71 75 76 72 71 60 66 72 
5 115 90 84 84 85 87 84 86 88 89 80 82 81 78 79 78 80 81 80 
6 76 70 89 64 63 66 69 69 60 68 62 68 69 70 72 74 72 70 74 
7 86 83 82 68 68 64 62 60 70 74 72 85 89 82 81 88 85 86 84 
8 92 80 71 76 74 71 76 75 74 72 80 76 73 79 71 76 70 85 86 
9 78 81 76 72 70 74 75 81 82 85 84 86 89 82 86 85 84 80 81 
10 102 100 70 71 66 64 68 60 56 84 89 86 76 74 75 70 68 70 72 
11 91 90 85 69 71 75 68 69 64 68 71 72 67 65 66 62 69 68 70 
12 83 85 75 84 74 72 75 71 74 70 75 79 78 76 85 82 81 80 75 
13 88 86 92 72 71 70 79 78 75 73 74 76 79 74 72 79 75 72 71 
14 80 81 82 68 64 65 60 55 52 60 62 69 60 54 52 50 52 53 51 
15 72 80 70 70 75 74 74 75 78 79 80 80 79 84 82 81 83 86 81 
16 110 88 86 72 81 81 86 83 84 82 76 79 81 83 72 71 74 76 75 
17 75 70 66 60 64 62 65 67 60 56 52 68 75 73 69 64 68 69 71 
18 72 78 74 76 69 71 72 75 74 71 78 79 75 76 71 70 78 75 78 
19 95 72 68 71 75 70 74 75 81 82 85 84 86 89 82 86 85 84 80 
20 83 88 72 70 72 66 64 68 60 56 84 89 86 76 74 75 70 68 70 
21 109 88 70 85 74 71 76 75 74 72 80 76 73 79 71 76 70 85 84 
22 81 74 62 66 70 74 75 81 82 85 84 86 89 82 86 85 84 80 84 
23 86 83 81 80 66 64 56 55 56 53 99 105 96 92 84 82 81 73 74 
24 92 82 82 83 71 75 68 69 64 68 71 72 67 65 66 62 69 68 69 
25 89 73 71 70 84 84 86 74 76 67 95 86 67 79 79 75 76 67 60 
   
S.
NO 
RESPIRATORY RATE (per MIN)-GROUP A 
BASE 
LINE 
 5 
MIN
S 
10 
MINS 
15 
MINS 
20 
MINS 
25 
MINS 
30 
MINS 
35 
MINS 
40 
MINS 
45 
MINS 
50 
MINS 
55 
MINS 
60 
MINS  
65 
MINS 
70 
MINS 
75 
MINS 
80 
MINS 
85MI
NS 
90 
MINS 
1 14 15 15 14 13 12 12 13 13 12 12 14 13 14 15 13 15 15 14 
2 13 12 14 13 14 12 14 12 12 13 14 12 13 15 14 12 13 12 13 
3 14 14 13 13 15 12 14 13 14 14 13 15 14 15 14 14 14 14 14 
4 15 14 14 14 13 14 13 14 13 14 14 15 14 14 14 14 14 14 14 
5 14 15 14 15 14 14 15 13 15 14 15 12 14 14 15 14 13 12 14 
6 14 14 13 13 12 13 12 13 13 12 13 12 12 12 13 13 14 13 14 
7 14 14 13 13 15 12 14 13 14 14 13 15 14 15 14 14 14 14 14 
8 14 15 15 14 13 12 12 13 13 12 12 14 13 14 15 13 15 15 14 
9 15 14 15 13 14 13 12 13 13 14 15 14 13 13 13 14 13 14 13 
10 15 14 15 14 13 14 14 14 13 12 14 14 13 12 14 13 14 14 13 
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23 14 14 14 14 14 14 14 14 14 14 13 14 14 14 14 14 14 14 14 
24 14 14 13 13 15 12 14 13 14 14 13 15 14 15 14 14 14 14 14 
25 15 14 14 14 13 14 13 14 13 14 14 15 14 14 14 14 14 14 14 
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2 0 0 0 0 2 
    
100 80 80 60 
  4 
  
2 0 0 0 0 2 
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80 80 60 
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4 99 99 99 99 99 99 99 99 99 98 99 99 99 99 99 99 99 99 99 
5 99 99 99 99 99 99 99 99 98 99 99 99 99 99 99 99 99 99 98 
6 99 99 99 99 99 99 99 99 98 98 98 98 98 98 98 98 98 98 98 
7 98 98 98 98 98 98 98 98 98 99 99 99 99 99 99 99 99 99 98 
8 99 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
9 98 98 98 98 98 98 98 98 99 99 99 99 99 99 99 99 99 99 99 
10 99 98 99 99 99 99 99 99 98 98 99 99 99 99 99 99 99 99 99 
11 98 98 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
12 99 98 99 99 99 99 99 99 98 98 99 99 98 98 98 98 98 98 98 
13 98 99 99 99 99 99 99 99 98 99 99 99 99 99 99 99 99 98 99 
14 99 98 98 98 98 98 99 99 99 98 99 99 99 99 99 99 99 98 99 
15 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
16 99 98 98 98 98 98 99 99 99 99 99 99 99 99 99 99 99 99 99 
17 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
18 98 98 98 98 98 98 99 99 99 99 99 98 99 99 99 99 99 98 99 
19 99 99 99 99 99 99 98 98 98 98 98 98 98 98 99 99 99 99 99 
20 99 99 99 99 99 99 99 99 99 98 99 98 99 99 99 99 98 99 98 
21 99 99 99 99 99 99 98 98 98 98 98 98 98 98 99 99 99 98 99 
22 99 99 99 99 99 99 99 99 99 98 99 99 99 98 99 99 99 98 98 
23 98 98 98 98 98 98 98 98 98 98 98 98 98 99 99 99 99 99 99 
24 98 98 98 98 98 98 99 99 99 99 99 99 99 98 99 99 99 99 98 
25 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
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4 99 99 99 97 99 99 99 98 99 99 99 98 98 99 99 99 99 99 99 
5 99 99 99 98 99 99 99 98 99 99 97 99 97 98 99 99 98 99 99 
6 99 98 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
7 98 97 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
8 99 98 99 99 99 99 98 99 99 99 98 99 99 99 99 98 99 99 98 
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11 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
12 99 98 99 98 99 99 97 98 99 99 98 98 98 99 99 99 99 99 99 
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15 99 99 99 99 99 99 98 99 99 99 99 99 99 99 99 98 99 99 98 
16 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
17 98 98 98 97 98 98 97 98 98 98 98 98 98 98 98 98 98 98 98 
18 99 99 99 99 99 99 99 99 99 98 99 99 99 99 99 99 99 99 99 
19 99 98 99 98 99 99 99 99 99 99 98 99 98 99 98 98 99 99 98 
20 98 97 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
21 98 98 98 98 98 98 99 98 98 98 98 98 98 98 98 98 98 98 98 
22 99 97 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
23 99 99 99 99 99 99 99 99 99 99 97 99 99 99 99 99 99 99 99 
24 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 98 
25 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
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A STUDY TO EVALUATE MAGNESIUM SULPHATE IN 
ACCELERATING THE ONSET OF ACTION OF INJECTION 
BUPIVACAINE USED FOR EPIDURAL ANAESTHESIA 
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ABSTRACT 
OBJECTIVE: To evaluate the effect of onset of action of magnesium sulphate in epidural                                   
anesthesia in patients coming for elective lower abdominal surgeries. 
 
METHOD: After institutional ethical committee clearance this  prospective randomised   
double blinded study was undertaken to establish the effect of addition of magnesium  as an 
adjuvant to epidural bupivacaine in lower abdominal surgeries. A total of 50 American 
Society of Anaesthesiology (ASA) grade I & II patients undergoing lower abdominal 
surgeries were enrolled to receive either magnesium sulphate (B) or 0.9 % Normal saline (A) 
along with epidural bupivacaine for surgical anaesthesia. All patients received 14 ml of 
epidural bupivacaine 0.5% along with 50 mg(1 ml) magnesium in group B, 0.9 % Normal 
saline (1 ml) in group A . Onset time ,heart rate, blood pressure, duration of analgesia, pain, 
assessment by visual analog score (VAS), RAM score and adverse effects were recorded. 
  
RESULTS:  Onset time of sensory blockade was rapid in magnesium group compared to the 
control group (11.20±2.17 vs 17.80±2.53, respectively). The time for two segment motor 
regression 84.00 ± 7.5 in the magnesium group and 51.00 ± 7.50 in the control group with a p 
value of <0.001 The groups were similar with respect to hemodynamic variables.  
 
CONCLUSION: The current study establishes magnesium sulphate as a predictable adjunct 
to epidural bupivacaine for rapid onset of anaesthesia with no adverse effects. 
 
Key words:    Bupivacaine, epidural anesthesia, Magnesium sulphate 
 
 
